

## Third Universal Definition of Myocardial Infarction

Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman, and Harvey D. White: the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction

### AUTHORS/TASK FORCE MEMBERS CHAIRPERSONS

Kristian Thygesen (Denmark),\* Joseph S. Alpert (USA),\* Harvey D. White (New Zealand),\* Biomarker Subcommittee: Allan S. Jaffe (USA), Hugo A. Katus (Germany), Fred S. Apple (USA), Bertil Lindahl (Sweden), David A. Morrow (USA), ECG Subcommittee: Bernard R. Chaitman (USA), Peter M. Clemmensen (Denmark), Per Johanson (Sweden), Hanoch Hod (Israel), Imaging Subcommittee: Richard Underwood (UK), Jeroen J. Bax (The Netherlands), Robert O. Bonow (USA), Fausto Pinto (Portugal), Raymond J. Gibbons (USA), Classification Subcommittee: Keith A. Fox (UK), Dan Atar (Norway), L. Kristin Newby (USA), Marcello Galvani (Italy), Christian W. Hamm (Germany), Intervention Subcommittee: Barry F. Uretsky (USA), Ph. Gabriel Steg (France), William Wijns (Belgium), Jean-Pierre Bassand (France), Philippe Menasché (France), Jan Ravkilde (Denmark), Trials & Registries Subcommittee: E. Magnus Ohman (USA), Elliott M. Antman (USA), Lars C. Wallentin (Sweden), Paul W. Armstrong (Canada), Maarten L. Simoons (The Netherlands), Heart Failure Subcommittee: James L. Januzzi (USA), Markku S. Nieminen (Finland), Mihai Gheorghide (USA), Gerasimos Filippatos (Greece), Epidemiology Subcommittee: Russell V. Luepker (USA), Stephen P. Fortmann (USA), Wayne D. Rosamond (USA), Dan Levy (USA), David Wood (UK), Global Perspective Subcommittee: Sidney C. Smith (USA), Dayi Hu (China), José-Luis Lopez-Sendon (Spain), Rose Marie Robertson (USA), Douglas Weaver (USA), Michal Tendera (Poland), Alfred A. Bove (USA), Alexander N. Parkhomenko (Ukraine), Elena J. Vasilieva (Russia), Shanti Mendis (Switzerland)

### ESC COMMITTEE FOR PRACTICE GUIDELINES (CPG)

Jeroen J. Bax (CPG Chairperson) (Netherlands), Helmut Baumgartner (Germany), Claudio Ceconi (Italy), Veronica Dean (France), Christi Deaton (UK), Robert Fagard (Belgium), Christian Funck-Brentano (France), David Hasdai (Israel), Arno Hoes (Netherlands), Paulus Kirchhof (Germany/UK), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Theresa McDonagh (UK), Cyril Moulin (France), Bogdan A. Popescu (Romania), Željko Reiner (Croatia), Udo Sechtem (Germany), Per Anton Sirnes (Norway), Michal Tendera (Poland), Adam Torbicki (Poland), Alec Vahanian (France), Stephan Windecker (Switzerland)

\*Corresponding authors/co-chairpersons: Professor Kristian Thygesen, Department of Cardiology, Aarhus University Hospital, Tage-Hansens Gade 2, DK-8000 Aarhus C, Denmark. Tel: +45 7846-7614; fax: +45 7846-7619; E-mail: kristhyg@rm.dk. Professor Joseph S. Alpert, Department of Medicine, Univ. of Arizona College of Medicine, 1501 N. Campbell Ave., P.O. Box 245037, Tucson AZ 85724, USA. Tel: +1 520 626 2763, Fax: +1 520 626 0967, E-mail: jalpert@email.arizona.edu. Professor Harvey D. White, Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, 1030 Auckland, New Zealand. Tel: +64 9 630 9992, Fax: +64 9 630 9915, E-mail: harveyw@adhb.govt.nz.

The European Society of Cardiology, American College of Cardiology Foundation, American Heart Association, and the World Heart Federation make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This document was approved by the European Society of Cardiology, American College of Cardiology Foundation, American Heart Association, and World Heart Federation in July 2012.

The American Heart Association requests that this document be cited as follows: Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. *Circulation*. 2012;126:2020–2035.

This article has been copublished in the *European Heart Journal*, *Journal of the American College of Cardiology*, and *Global Heart*.

Copies: This document is available on the World Wide Web sites of the European Society of Cardiology ([www.escardio.org](http://www.escardio.org)), American College of Cardiology ([www.cardiosource.org](http://www.cardiosource.org)), American Heart Association ([my.americanheart.org](http://my.americanheart.org)), and the World Heart Federation ([www.world-heart-federation.org](http://www.world-heart-federation.org)). A copy of the document is available at <http://my.americanheart.org/statements> by selecting either the “By Topic” link or the “By Publication Date” link. To purchase additional reprints, call 843-216-2533 or e-mail [kelle.ramsay@wolterskluwer.com](mailto:kelle.ramsay@wolterskluwer.com).

The disclosure forms of the authors and reviewers are available as a [Data Supplement](#) on the *Circulation* Web site.

**The online-only Data Supplement is available with this article at <http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0b013e31826e1058/-DC1>.**

Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <http://my.americanheart.org/statements> and select the “Policies and Development” link.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at [http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines\\_UCM\\_300404\\_Article.jsp](http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp). A link to the “Copyright Permissions Request Form” appears on the right side of the page.

(*Circulation*. 2012;126:2020–2035.)

© 2012 by The European Society of Cardiology, American College of Cardiology Foundation, American Heart Association, Inc., and the World Heart Federation.

*Circulation* is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIR.0b013e31826e1058

DOCUMENT REVIEWERS

Joao Morais (CPG Review Co-ordinator) (Portugal), Carlos Aguiar (Portugal), Wael Almahmeed (United Arab Emirates), David O. Arnar (Iceland), Fabio Barili (Italy), Kenneth D. Bloch (USA), Ann F. Bolger (USA), Hans Erik Bøtker (Denmark), Biykem Bozkurt (USA), Raffaele Bugiardini (Italy), Christopher Cannon (USA), James de Lemos (USA), Franz R. Eberli (Switzerland), Edgardo Escobar (Chile), Mark Hlatky (USA), Stefan James (Sweden), Karl B. Kern (USA), David J. Moliterno (USA), Christian Mueller (Switzerland), Aleksandar N. Neskovic (Serbia), Burkert Mathias Pieske (Austria), Steven P. Schulman (USA), Robert F. Storey (UK), Kathryn A. Taubert (Switzerland), Pascal Vranckx (Belgium), Daniel R. Wagner (Luxembourg)

Table of Contents

Abbreviations and Acronyms .....2021  
 Definition of Myocardial Infarction .....2022  
 Criteria for Acute Myocardial Infarction.....2022  
 Criteria for Prior Myocardial Infarction .....2022  
 Introduction.....2022  
 Pathological Characteristics of Myocardial Ischaemia and Infarction .....2023  
 Biomarker Detection of Myocardial Injury With Necrosis. .2023  
 Clinical Features of Myocardial Ischaemia and Infarction . .2024  
 Clinical Classification of Myocardial Infarction . . . .2024  
     Spontaneous Myocardial Infarction (MI Type 1) . . .2024  
     Myocardial Infarction Secondary to an Ischaemic Imbalance (MI Type 2) . . . . .2024  
     Cardiac Death Due to Myocardial Infarction (MI Type 3) .2025  
     Myocardial Infarction Associated With Revascularization Procedures (MI Types 4 and 5) . . . . .2026  
 Electrocardiographic Detection of Myocardial Infarction.2026  
 Prior Myocardial Infarction.....2027  
 Silent Myocardial Infarction .....2027  
 Conditions that Confound the ECG Diagnosis of Myocardial Infarction .....2027  
 Imaging Techniques .....2027  
     Echocardiography .....2028  
     Radionuclide Imaging .....2028  
     Magnetic Resonance Imaging .....2028  
     Computed Tomography.....2028  
     Applying Imaging in Acute Myocardial Infarction .2028  
     Applying Imaging in Late Presentation of Myocardial Infarction .....2029  
 Diagnostic Criteria for Myocardial Infarction With PCI (MI Type 4).....2029  
 Diagnostic Criteria for Myocardial Infarction With CABG (MI Type 5) .....2029  
 Assessment of MI in Patients Undergoing Other Cardiac Procedures .....2030  
 Myocardial Infarction Associated With Non-Cardiac Procedures .....2030  
 Myocardial Infarction in the Intensive Care Unit . . . .2030  
 Recurrent Myocardial Infarction .....2030  
 Reinfarction.....2030  
 Myocardial Injury or Infarction Associated With Heart Failure .....2031  
 Application of MI in Clinical Trials and Quality Assurance Programmes.....2031  
 Public Policy Implications of the Adjustment of the MI Definition. ....2031  
 Global Perspectives of the Definition of Myocardial Infarction .....2032  
 Conflicts of Interest.....2032  
 Acknowledgments.....2033  
 References.....2033

Abbreviations and Acronyms

---

ACCF	American College of Cardiology Foundation
ACS	acute coronary syndrome
AHA	American Heart Association
CAD	coronary artery disease
CABG	coronary artery bypass grafting
CKMB	creatinine kinase MB isoform
cTn	cardiac troponin
CT	computed tomography
CV	coefficient of variation
ECG	electrocardiogram
ESC	European Society of Cardiology
FDG	fluorodeoxyglucose
h	hour(s)
HF	heart failure
LBBB	left bundle branch block
LV	left ventricle
LVH	left ventricular hypertrophy
MI	myocardial infarction
mIBG	meta-iodo-benzylguanidine
min	minute(s)
MONICA	Multinational MONItoring of trends and determinants in Cardiovascular disease
MPS	myocardial perfusion scintigraphy
MRI	magnetic resonance imaging
mV	millivolt(s)
ng/L	nanogram(s) per litre
Non-Q MI	non-Q wave myocardial infarction
NSTEMI	non-ST-elevation myocardial infarction
PET	positron emission tomography
pg/mL	pictogram(s) per millilitre
PCI	percutaneous coronary intervention
Q wave MI	Q wave myocardial infarction
RBBB	right bundle branch block
sec	second(s)
SPECT	single photon emission computed tomography
STEMI	ST elevation myocardial infarction
ST-T	ST-segment-T wave
URL	upper reference limit
WHF	World Heart Federation
WHO	World Health Organization

---

### Definition of myocardial infarction

#### Criteria for acute myocardial infarction

The term acute myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischaemia. Under these conditions any one of the following criteria meets the diagnosis for MI:

- Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one value above the 99<sup>th</sup> percentile upper reference limit (URL) and with at least one of the following:
  - ◆ Symptoms of ischaemia.
  - ◆ New or presumed new significant ST-segment–T wave (ST–T) changes or new left bundle branch block (LBBB).
  - ◆ Development of pathological Q waves in the ECG.
  - ◆ Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
  - ◆ Identification of an intracoronary thrombus by angiography or autopsy.
- Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or new LBBB, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased.
- Percutaneous coronary intervention (PCI) related MI is arbitrarily defined by elevation of cTn values (>5 × 99<sup>th</sup> percentile URL) in patients with normal baseline values (≤99<sup>th</sup> percentile URL) or a rise of cTn values >20% if the baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischaemia or (ii) new ischaemic ECG changes or (iii) angiographic findings consistent with a procedural complication or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are required.
- Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a rise and/or fall of cardiac biomarker values with at least one value above the 99<sup>th</sup> percentile URL.
- Coronary artery bypass grafting (CABG) related MI is arbitrarily defined by elevation of cardiac biomarker values (>10 × 99<sup>th</sup> percentile URL) in patients with normal baseline cTn values (≤99<sup>th</sup> percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

#### Criteria for prior myocardial infarction

Any one of the following criteria meets the diagnosis for prior MI:

- Pathological Q waves with or without symptoms in the absence of non-ischaemic causes.
- Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischaemic cause.
- Pathological findings of a prior MI.

## Introduction

Myocardial infarction (MI) can be recognised by clinical features, including electrocardiographic (ECG) findings, elevated values of biochemical markers (biomarkers) of myocardial necrosis, and by imaging, or may be defined by pathology. It is a major cause of death and disability worldwide. MI may be the first manifestation of coronary artery disease (CAD) or it may occur, repeatedly, in patients with established disease. Information on MI rates can provide useful information regarding the burden of CAD within and across populations, especially if standardized data are collected in a manner that distinguishes between incident and recurrent events. From the epidemiological point of view, the incidence of MI in a population can be used as a proxy for the prevalence of CAD in that population. The term ‘myocardial infarction’ may have major psychological and legal implications for the individual and society. It is an indicator of one of the leading health problems in the world and it is an outcome measure in clinical trials, observational studies and quality assurance programmes. These studies and programmes require a precise and consistent definition of MI.

In the past, a general consensus existed for the clinical syndrome designated as MI. In studies of disease prevalence, the World Health Organization (WHO) defined MI from symptoms, ECG abnormalities and cardiac enzymes. However, the development of ever more sensitive and myocardial tissue-specific cardiac biomarkers and more sensitive imaging techniques now allows for detection of very small

amounts of myocardial injury or necrosis. Additionally, the management of patients with MI has significantly improved, resulting in less myocardial injury and necrosis, in spite of a similar clinical presentation. Moreover, it appears necessary to distinguish the various conditions which may cause MI, such as ‘spontaneous’ and ‘procedure-related’ MI. Accordingly, physicians, other healthcare providers and patients require an up-to-date definition of MI.

In 2000, the First Global MI Task Force presented a new definition of MI, which implied that any necrosis in the setting of myocardial ischaemia should be labelled as MI.<sup>1</sup> These principles were further refined by the Second Global MI Task Force, leading to the Universal Definition of Myocardial Infarction Consensus Document in 2007, which emphasized the different conditions which might lead to an MI.<sup>2</sup> This document, endorsed by the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF), has been well accepted by the medical community and adopted by the WHO.<sup>3</sup> However, the development of even more sensitive assays for markers of myocardial necrosis mandates further revision, particularly when such necrosis occurs in the setting of the critically ill, after percutaneous coronary procedures or after cardiac surgery. The Third Global MI Task Force has continued the Joint ESC/ACCF/AHA/WHF efforts by integrating these insights and new data into the current document, which now recognizes that very small amounts of myocardial

injury or necrosis can be detected by biochemical markers and/or imaging.

### Pathological Characteristics of Myocardial Ischaemia and Infarction


MI is defined in pathology as myocardial cell death due to prolonged ischaemia. After the onset of myocardial ischaemia, histological cell death is not immediate, but takes a finite period of time to develop—as little as 20 min, or less in some animal models.<sup>4</sup> It takes several hours before myocardial necrosis can be identified by macroscopic or microscopic post-mortem examination. Complete necrosis of myocardial cells at risk requires at least 2–4 h, or longer, depending on the presence of collateral circulation to the ischaemic zone, persistent or intermittent coronary arterial occlusion, the sensitivity of the myocytes to ischaemia, pre-conditioning, and individual demand for oxygen and nutrients.<sup>2</sup> The entire process leading to a healed infarction usually takes at least 5–6 weeks. Reperfusion may alter the macroscopic and microscopic appearance.

### Biomarker Detection of Myocardial Injury With Necrosis

Myocardial injury is detected when blood levels of sensitive and specific biomarkers such as cTn or the MB fraction of creatine kinase (CKMB) are increased.<sup>2</sup> Cardiac troponin I and T are components of the contractile apparatus of myocardial cells and are expressed almost exclusively in the heart. Although elevations of these biomarkers in the blood reflect injury leading to necrosis of myocardial cells, they do not indicate the underlying mechanism.<sup>5</sup> Various possibilities have been suggested for release of structural proteins from the myocardium, including normal turnover of myocardial cells, apoptosis, cellular release of troponin degradation products, increased cellular wall permeability, formation and release of membranous blebs, and myocyte necrosis.<sup>6</sup> Regardless of the pathobiology, myocardial necrosis due to myocardial ischaemia is designated as MI.

Also, histological evidence of myocardial injury with necrosis may be detectable in clinical conditions associated with predominantly non-ischaemic myocardial injury. Small amounts of myocardial injury with necrosis may be detected, which are associated with heart failure (HF), renal failure, myocarditis, arrhythmias, pulmonary embolism or otherwise uneventful percutaneous or surgical coronary procedures. These should not be labelled as MI or a complication of the procedures, but rather as myocardial injury, as illustrated in Figure 1. It is recognized that the complexity of clinical circumstances may sometimes render it difficult to determine where individual cases may lie within the ovals of Figure 1. In this setting, it is important to distinguish acute causes of cTn elevation, which require a rise and/or fall of cTn values, from chronic elevations that tend not to change acutely. A list of such clinical circumstances associated with elevated values of cTn is presented in Table 1. The multifactorial contributions resulting in the myocardial injury should be described in the patient record.

The preferred biomarker—overall and for each specific category of MI—is cTn (I or T), which has high myocardial



**Figure 1.** This illustration shows various clinical entities: for example, renal failure, heart failure, tachy- or bradyarrhythmia, cardiac or non-cardiac procedures that can be associated with myocardial injury with cell death marked by cardiac troponin elevation. However, these entities can also be associated with myocardial infarction in case of clinical evidence of acute myocardial ischaemia with rise and/or fall of cardiac troponin.

tissue specificity as well as high clinical sensitivity. Detection of a rise and/or fall of the measurements is essential to the diagnosis of acute MI.<sup>7</sup> An increased cTn concentration is defined as a value **exceeding the 99th percentile of a normal reference population [upper reference limit (URL)]**. This discriminatory 99th percentile is designated as the decision level for the diagnosis of MI and must be determined for each specific assay with appropriate quality control in each laboratory.<sup>8,9</sup> The values for the 99th percentile URL defined by manufacturers, including those for many of the high-sensitivity assays in development, can be found in the package inserts for the assays or in recent publications.<sup>10,11,12</sup>

Values should be presented as nanograms per litre (ng/L) or picograms per millilitre (pg/mL) to make whole numbers. Criteria for the rise of cTn values are assay-dependent but can be defined from the precision profile of each individual assay, including high-sensitivity assays.<sup>10,11</sup> **Optimal precision** as described by **coefficient of variation (CV)** at the 99th percentile URL for each assay, should be defined as **≤10%**. Better precision (CV ≤10%) allows for more sensitive assays and facilitates the detection of changing values.<sup>13</sup> The use of assays that do not have optimal precision (CV >10% at the 99th percentile URL) makes determination of a significant change more difficult but does not cause false positive results. Assays with CV >20% at the 99th percentile URL should not be used.<sup>13</sup> It is acknowledged that pre-analytic and analytic problems can induce elevated and reduced values of cTn.<sup>10,11</sup>

Blood samples for the measurement of cTn should be drawn on **first assessment** and repeated **3–6 h later**. Later samples are required if further ischaemic episodes occur, or when the timing of the initial symptoms is unclear.<sup>14</sup> To establish the diagnosis of MI, a rise and/or fall in values with at least one value above the decision level is required, coupled with a **strong pre-test likelihood**. The demonstration of a rising and/or falling pattern is needed to distinguish

**Table 1. Elevations of Cardiac Troponin Values Because of Myocardial Injury**

<b>Injury related to primary myocardial ischaemia</b>
Plaque rupture Intraluminal coronary artery thrombus formation
<b>Injury related to supply/demand imbalance of myocardial ischaemia</b>
Tachy-/brady-arrhythmias Aortic dissection or severe aortic valve disease Hypertrophic cardiomyopathy Cardiogenic, hypovolaemic, or septic shock Severe respiratory failure Severe anaemia Hypertension with or without LVH Coronary spasm Coronary embolism or vasculitis Coronary endothelial dysfunction without significant CAD
<b>Injury not related to myocardial ischaemia</b>
Cardiac contusion, surgery, ablation, pacing, or defibrillator shocks Rhabdomyolysis with cardiac involvement Myocarditis Cardiotoxic agents, e.g. anthracyclines, herceptin
<b>Multifactorial or indeterminate myocardial injury</b>
Heart failure Stress (Takotsubo) cardiomyopathy Severe pulmonary embolism or pulmonary hypertension Sepsis and critically ill patients Renal failure Severe acute neurological diseases, e.g. stroke, subarachnoid haemorrhage Infiltrative diseases, e.g. amyloidosis, sarcoidosis Strenuous exercise

acute-from chronic elevations in cTn concentrations that are associated with structural heart disease.<sup>10,11,15–19</sup> For example, patients with renal failure or HF can have significant chronic elevations in cTn. These elevations can be marked, as seen in many patients with MI, but do not change acutely.<sup>7</sup> However, a rising or falling pattern is not absolutely necessary to make the diagnosis of MI if a patient with a high pre-test risk of MI presents late after symptom onset; for example, near the peak of the cTn time-concentration curve or on the slow-declining portion of that curve, when detecting a changing pattern can be problematic. Values may remain elevated for 2 weeks or more following the onset of myocyte necrosis.<sup>10</sup>

Sex-dependent values may be recommended for high-sensitivity troponin assays.<sup>20,21</sup> An elevated cTn value (>99th percentile URL), with or without a dynamic pattern of values or in the absence of clinical evidence of ischaemia, should prompt a search for other diagnoses associated with myocardial injury, such as myocarditis, aortic dissection, pulmonary embolism, or HF. Renal failure and other more non-ischaemic chronic disease states, that can be associated with elevated cTn levels, are listed in Table 1.<sup>10,11</sup>

If a cTn assay is not available, the best alternative is CKMB (measured by mass assay). As with troponin, an

increased CKMB value is defined as a measurement above the 99th percentile URL, which is designated as the decision level for the diagnosis of MI.<sup>22</sup> Sex-specific values should be employed.<sup>22</sup>

### Clinical Features of Myocardial Ischaemia and Infarction

Onset of myocardial ischaemia is the initial step in the development of MI and results from an imbalance between oxygen supply and demand. Myocardial ischaemia in a clinical setting can usually be identified from the patient's history and from the ECG. Possible ischaemic symptoms include various combinations of chest, upper extremity, mandibular or epigastric discomfort (with exertion or at rest) or an ischaemic equivalent such as dyspnoea or fatigue. The discomfort associated with acute MI usually lasts >20 min. Often, the discomfort is diffuse—not localized, nor positional, nor affected by movement of the region—and it may be accompanied by diaphoresis, nausea or syncope. However, these symptoms are not specific for myocardial ischaemia. Accordingly, they may be misdiagnosed and attributed to gastrointestinal, neurological, pulmonary or musculoskeletal disorders. MI may occur with atypical symptoms—such as palpitations or cardiac arrest—or even without symptoms; for example in women, the elderly, diabetics, or post-operative and critically ill patients.<sup>2</sup> Careful evaluation of these patients is advised, especially when there is a rising and/or falling pattern of cardiac biomarkers.

### Clinical Classification of Myocardial Infarction

For the sake of immediate treatment strategies, such as reperfusion therapy, it is usual practice to designate MI in patients with chest discomfort, or other ischaemic symptoms that develop ST elevation in two contiguous leads (see ECG section), as an 'ST elevation MI' (STEMI). In contrast, patients without ST elevation at presentation are usually designated as having a 'non-ST elevation MI' (NSTEMI). Many patients with MI develop Q waves (Q wave MI), but others do not (non-Q MI). Patients without elevated biomarker values can be diagnosed as having unstable angina. In addition to these categories, MI is classified into various types, based on pathological, clinical and prognostic differences, along with different treatment strategies (Table 2).

#### Spontaneous Myocardial Infarction (MI Type 1)

This is an event related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries, leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis. The patient may have underlying severe CAD but, on occasion (5 to 20%), non-obstructive or no CAD may be found at angiography, particularly in women.<sup>23–25</sup>

#### Myocardial Infarction Secondary to an Ischaemic Imbalance (MI Type 2)

In instances of myocardial injury with necrosis, where a condition *other than CAD* contributes to an imbalance be-


**Table 2. Universal Classification of Myocardial Infarction**

<p><b>Type 1: Spontaneous myocardial infarction</b></p> <p>Spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis. The patient may have underlying severe CAD but on occasion non-obstructive or no CAD.</p>
<p><b>Type 2: Myocardial infarction secondary to an ischaemic imbalance</b></p> <p>In instances of myocardial injury with necrosis where a condition other than CAD contributes to an imbalance between myocardial oxygen supply and/or demand, e.g. coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachy-/brady-arrhythmias, anaemia, respiratory failure, hypotension, and hypertension with or without LVH.</p>
<p><b>Type 3: Myocardial infarction resulting in death when biomarker values are unavailable</b></p> <p>Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or new LBBB, but death occurring before blood samples could be obtained, before cardiac biomarker could rise, or in rare cases cardiac biomarkers were not collected.</p>
<p><b>Type 4a: Myocardial infarction related to percutaneous coronary intervention (PCI)</b></p> <p>Myocardial infarction associated with PCI is arbitrarily defined by elevation of cTn values &gt;5 x 99<sup>th</sup> percentile URL in patients with normal baseline values (≤99<sup>th</sup> percentile URL) or a rise of cTn values &gt;20% if the baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischaemia, or (ii) new ischaemic ECG changes or new LBBB, or (iii) angiographic loss of patency of a major coronary artery or a side branch or persistent slow- or no-flow or embolization, or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are required.</p>
<p><b>Type 4b: Myocardial infarction related to stent thrombosis</b></p> <p>Myocardial infarction associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a rise and/or fall of cardiac biomarkers values with at least one value above the 99<sup>th</sup> percentile URL.</p>
<p><b>Type 5: Myocardial infarction related to coronary artery bypass grafting (CABG)</b></p> <p>Myocardial infarction associated with CABG is arbitrarily defined by elevation of cardiac biomarker values &gt;10 x 99<sup>th</sup> percentile URL in patients with normal baseline cTn values (≤99<sup>th</sup> percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.</p>

tween myocardial oxygen supply and/or demand, the term ‘MI type 2’ is employed (Figure 2). In critically ill patients, or in patients undergoing major (non-cardiac) surgery, elevated values of cardiac biomarkers may appear, due to the direct toxic effects of endogenous or exogenous high circulating catecholamine levels. Also coronary vasospasm and/or endothelial dysfunction have the potential to cause MI.<sup>26–28</sup>

**Cardiac Death Due to Myocardial Infarction (MI Type 3)**

Patients who suffer cardiac death, with symptoms suggestive of myocardial ischaemia accompanied by presumed new ischaemic ECG changes or new LBBB—but without available biomarker values—represent a challenging diagnostic group. These individuals may die before blood samples for



**Figure 2. Differentiation between myocardial infarction (MI) types 1 and 2 according to the condition of the coronary arteries.**

biomarkers can be obtained, or before elevated cardiac biomarkers can be identified. If patients present with clinical features of myocardial ischaemia, or with presumed new ischaemic ECG changes, they should be classified as having had a fatal MI, even if cardiac biomarker evidence of MI is lacking.

### Myocardial Infarction Associated With Revascularization Procedures (MI Types 4 and 5)

Periprocedural myocardial injury or infarction may occur at some stages in the instrumentation of the heart that is required during mechanical revascularization procedures, either by PCI or by coronary artery bypass grafting (CABG). Elevated cTn values may be detected following these procedures, since various insults may occur that can lead to myocardial injury with necrosis.<sup>29–32</sup> It is likely that limitation of such injury is beneficial to the patient: however, a threshold for a worsening prognosis, related to an asymptomatic increase of cardiac biomarker values in the absence of procedural complications, is not well defined.<sup>33–35</sup> Subcategories of PCI-related MI are connected to stent thrombosis and restenosis that may happen after the primary procedure.

### Electrocardiographic Detection of Myocardial Infarction

The ECG is an integral part of the diagnostic work-up of patients with suspected MI and should be acquired and interpreted promptly (i.e. target within 10 min) after clinical presentation.<sup>2</sup> Dynamic changes in the ECG waveforms during acute myocardial ischaemic episodes often require acquisition of multiple ECGs, particularly if the ECG at initial presentation is non-diagnostic. Serial recordings in symptomatic patients with an initial non-diagnostic ECG should be performed at 15–30 min intervals or, if available, continuous computer-assisted 12-lead ECG recording. Recurrence of symptoms after an asymptomatic interval are an indication for a repeat tracing and, in patients with evolving ECG abnormalities, a pre-discharge ECG should be acquired as a baseline for future comparison. Acute or evolving changes in the ST-T waveforms and Q waves, when present, potentially allow the clinician to time the event, to identify the infarct-related artery, to estimate the amount of myocardium at risk as well as prognosis, and to determine therapeutic strategy. More profound ST-segment shift or T wave inversion involving multiple leads/territories is associated with a greater degree of myocardial ischaemia and a worse prognosis. Other ECG signs associated with acute myocardial ischaemia include cardiac arrhythmias, intraventricular and atrioventricular conduction delays, and loss of pre-cordial R wave amplitude. Coronary artery size and distribution of arterial segments, collateral vessels, location, extent and severity of coronary stenosis, and prior myocardial necrosis can all impact ECG manifestations of myocardial ischaemia.<sup>36</sup> Therefore the ECG at presentation should always be compared to prior ECG tracings, when available. The ECG by itself is often insufficient to diagnose acute myocardial ischaemia or infarction, since ST deviation may be observed in other conditions, such as acute pericarditis, left ventricular hypertrophy (LVH), left bundle branch block (LBBB), Brugada syndrome, stress cardiomyopathy, and early repolarization patterns.<sup>37</sup> Prolonged new ST-segment elevation (e.g. >20 min), particularly when associated with reciprocal

**Table 3. ECG Manifestations of Acute Myocardial Ischaemia**

ST elevation
New ST elevation at the J point in two contiguous leads with the cut-points: $\geq 0.1$ mV in all leads other than leads $V_2$ – $V_3$ where the following cut points apply: $\geq 0.2$ mV in men $\geq 40$ years; $\geq 0.25$ mV in men $< 40$ years, or $\geq 0.15$ mV in women.
ST depression and T wave changes
New horizontal or down-sloping ST depression $\geq 0.05$ mV in two contiguous leads and/or T inversion $\geq 0.1$ mV in two contiguous leads with prominent R wave or R/S ratio $> 1$ .

ST-segment depression, usually reflects acute coronary occlusion and results in myocardial injury with necrosis. As in cardiomyopathy, Q waves may also occur due to myocardial fibrosis in the absence of CAD.

ECG abnormalities of myocardial ischaemia or infarction may be inscribed in the PR segment, the QRS complex, the ST-segment or the T wave. The earliest manifestations of myocardial ischaemia are typically T wave and ST-segment changes. Increased hyperacute T wave amplitude, with prominent symmetrical T waves in at least two contiguous leads, is an early sign that may precede the elevation of the ST-segment. Transient Q waves may be observed during an episode of acute ischaemia or (rarely) during acute MI with successful reperfusion. Table 3 lists ST-T wave criteria for the diagnosis of acute myocardial ischaemia that may or may not lead to MI. The J point is used to determine the magnitude of the ST-segment shift. New, or presumed new, J point elevation  $\geq 0.1$  mV is required in all leads other than  $V_2$  and  $V_3$ . In healthy men under age 40, J-point elevation can be as much as 0.25 mV in leads  $V_2$  or  $V_3$ , but it decreases with increasing age. Sex differences require different cut-points for women, since J point elevation in healthy women in leads  $V_2$  and  $V_3$  is less than in men.<sup>38</sup> ‘Contiguous leads’ refers to lead groups such as anterior leads ( $V_1$ – $V_6$ ), inferior leads (II, III, aVF) or lateral/apical leads (I, aVL). Supplemental leads such as  $V_3R$  and  $V_4R$  reflect the free wall of the right ventricle and  $V_7$ – $V_9$  the infero-basal wall.

The criteria in Table 3 require that the ST shift be present in two or more contiguous leads. For example,  $\geq 0.2$  mV of ST elevation in lead  $V_2$ , and  $\geq 0.1$  mV in lead  $V_1$ , would meet the criteria of two abnormal contiguous leads in a man  $> 40$  years old. However,  $\geq 0.1$  mV and  $< 0.2$  mV of ST elevation, seen only in leads  $V_2$ – $V_3$  in men (or  $< 0.15$  mV in women), may represent a normal finding. It should be noted that, occasionally, acute myocardial ischaemia may create sufficient ST-segment shift to meet the criteria in one lead but have slightly less than the required ST shift in a contiguous lead. Lesser degrees of ST displacement or T wave inversion do not exclude acute myocardial ischaemia or evolving MI, since a single static recording may miss the more dynamic ECG changes that might be detected with serial recordings. ST elevation or diagnostic Q waves in contiguous lead groups are more specific than ST depression in localizing the site of myocardial ischaemia or necrosis.<sup>39,40</sup> Supplemental leads, as well as serial ECG recordings, should always be considered in patients that present with

**Table 4. ECG Changes Associated With Prior Myocardial Infarction (in Absence of LVH and LBBB)**

Any Q wave in leads $V_2-V_3 \geq 0.02$ sec or QS complex in leads $V_2$ and $V_3$ .
Q wave $\geq 0.03$ sec and $\geq 0.1$ mV deep or QS complex in leads I, II, aVL, aVF or $V_4-V_6$ in any two leads of a contiguous lead grouping (I, aVL; $V_1-V_6$ ; II, III, aVF). <sup>a</sup>
R wave $\geq 0.04$ sec in $V_1-V_2$ and R/S $\geq 1$ with a concordant positive T wave in absence of conduction defect.

<sup>a</sup>The same criteria are used for supplemental leads V7–V9.

ischaemic chest pain and a non-diagnostic initial ECG.<sup>41,42</sup> Electrocardiographic evidence of myocardial ischaemia in the distribution of a left circumflex artery is often overlooked and is best captured using posterior leads at the fifth intercostal space ( $V_7$  at the left posterior axillary line,  $V_8$  at the left mid-scapular line, and  $V_9$  at the left paraspinal border). Recording of these leads is strongly recommended in patients with high clinical suspicion for acute circumflex occlusion (for example, initial ECG non-diagnostic, or ST-segment depression in leads  $V_{1-3}$ ).<sup>41</sup> A cut-point of 0.05 mV ST elevation is recommended in leads  $V_7-V_9$ ; specificity is increased at a cut-point  $\geq 0.1$  mV ST elevation and this cut-point should be used in men <40 years old. ST depression in leads  $V_1-V_3$  may be suggestive of infero-basal myocardial ischaemia (posterior infarction), especially when the terminal T wave is positive (ST elevation equivalent), however this is non-specific.<sup>41–43</sup> In patients with inferior and suspected right ventricular infarction, right precordial leads  $V_3R$  and  $V_4R$  should be recorded, since ST elevation  $\geq 0.05$  mV ( $\geq 0.1$  mV in men <30 years old) provides supportive criteria for the diagnosis.<sup>42</sup>

During an episode of acute chest discomfort, pseudo-normalization of previously inverted T waves may indicate acute myocardial ischaemia. Pulmonary embolism, intracranial processes, electrolyte abnormalities, hypothermia, or peri-/myocarditis may also result in ST-T abnormalities and should be considered in the differential diagnosis. The diagnosis of MI is more difficult in the presence of LBBB.<sup>44,45</sup> However, concordant ST-segment elevation or a previous ECG may be helpful to determine the presence of acute MI in this setting. In patients with right bundle branch block (RBBB), ST-T abnormalities in leads  $V_1-V_3$  are common, making it difficult to assess the presence of ischaemia in these leads: however, when new ST elevation or Q waves are found, myocardial ischaemia or infarction should be considered.

**Prior Myocardial Infarction**

As shown in Table 4, Q waves or QS complexes in the absence of QRS confounders are pathognomonic of a prior MI in patients with ischaemic heart disease, regardless of symptoms.<sup>46,47</sup> The specificity of the ECG diagnosis for MI is greatest when Q waves occur in several leads or lead groupings. When the Q waves are associated with ST deviations or T wave changes in the same leads, the likelihood of MI is increased; for example, minor Q waves  $\geq 0.02$  sec and  $< 0.03$  sec that are  $\geq 0.1$  mV deep are suggestive of prior MI if accompanied by inverted T waves in the same lead group. Other validated MI coding algorithms,

**Table 5. Common ECG Pitfalls in Diagnosing Myocardial Infarction**

<b>False positives</b>
<ul style="list-style-type: none"> <li>• Early repolarization</li> <li>• LBBB</li> <li>• Pre-excitation</li> <li>• J point elevation syndromes, e.g. Brugada syndrome</li> <li>• Peri-/myocarditis</li> <li>• Pulmonary embolism</li> <li>• Subarachnoid haemorrhage</li> <li>• Metabolic disturbances such as hyperkalaemia</li> <li>• Cardiomyopathy</li> <li>• Lead transposition</li> <li>• Cholecystitis</li> <li>• Persistent juvenile pattern</li> <li>• Malposition of precordial ECG electrodes</li> <li>• Tricyclic antidepressants or phenothiazines</li> </ul>
<b>False negatives</b>
<ul style="list-style-type: none"> <li>• Prior MI with Q-waves and/or persistent ST elevation</li> <li>• Right ventricular pacing</li> <li>• LBBB</li> </ul>

such as the Minnesota Code and WHO MONICA, have been used in epidemiological studies and clinical trials.<sup>3</sup>

**Silent Myocardial Infarction**

Asymptomatic patients who develop new pathologic Q wave criteria for MI detected during routine ECG follow-up, or reveal evidence of MI by cardiac imaging, that cannot be directly attributed to a coronary revascularization procedure, should be termed ‘silent MI.’<sup>48–51</sup> In studies, silent Q wave MI accounted for 9–37% of all non-fatal MI events and were associated with a significantly increased mortality risk.<sup>48,49</sup> Improper lead placement or QRS confounders may result in what appear to be new Q waves or QS complexes, as compared to a prior tracing. Thus, the diagnosis of a new silent Q wave MI should be confirmed by a repeat ECG with correct lead placement, or by an imaging study, and by focussed questioning about potential interim ischaemic symptoms.

**Conditions That Confound the ECG Diagnosis of Myocardial Infarction**

A QS complex in lead  $V_1$  is normal. A Q wave  $< 0.03$  sec and  $< 25\%$  of the R wave amplitude in lead III is normal if the frontal QRS axis is between  $-30^\circ$  and  $0^\circ$ . A Q wave may also be normal in aVL if the frontal QRS axis is between  $60^\circ$  and  $90^\circ$ . Septal Q waves are small, non-pathological Q waves  $< 0.03$  sec and  $< 25\%$  of the R-wave amplitude in leads I, aVL, aVF, and  $V_4-V_6$ . Pre-excitation, obstructive, dilated or stress cardiomyopathy, cardiac amyloidosis, LBBB, left anterior hemiblock, LVH, right ventricular hypertrophy, myocarditis, acute *cor pulmonale*, or hyperkalaemia may be associated with Q waves or QS complexes in the absence of MI. ECG abnormalities that mimic myocardial ischaemia or MI are presented in Table 5.

**Imaging Techniques**

Non-invasive imaging plays many roles in patients with known or suspected MI, but this section concerns only its role

in the diagnosis and characterisation of MI. The underlying rationale is that regional myocardial hypoperfusion and ischaemia lead to a cascade of events, including myocardial dysfunction, cell death and healing by fibrosis. Important imaging parameters are therefore perfusion, myocyte viability, myocardial thickness, thickening and motion, and the effects of fibrosis on the kinetics of paramagnetic or radioopaque contrast agents.

Commonly used imaging techniques in acute and chronic infarction are echocardiography, radionuclide ventriculography, myocardial perfusion scintigraphy (MPS) using single photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Positron emission tomography (PET) and X-ray computed tomography (CT) are less common.<sup>52</sup> There is considerable overlap in their capabilities and each of the techniques can, to a greater or lesser extent, assess myocardial viability, perfusion, and function. Only the radionuclide techniques provide a direct assessment of myocyte viability, because of the inherent properties of the tracers used. Other techniques provide indirect assessments of myocardial viability, such as contractile response to dobutamine by echocardiography or myocardial fibrosis by MR.

### Echocardiography

The strength of echocardiography is the assessment of cardiac structure and function, in particular myocardial thickness, thickening and motion. Echocardiographic contrast agents can improve visualisation of the endocardial border and can be used to assess myocardial perfusion and microvascular obstruction. Tissue Doppler and strain imaging permit quantification of global and regional function.<sup>53</sup> Intravascular echocardiographic contrast agents have been developed that target specific molecular processes, but these techniques have not yet been applied in the setting of MI.<sup>54</sup>

### Radionuclide Imaging

Several radionuclide tracers allow viable myocytes to be imaged directly, including the SPECT tracers thallium-201, technetium-99m MIBI and tetrofosmin, and the PET tracers F-2-fluorodeoxyglucose (FDG) and rubidium-82.<sup>18,52</sup> The strength of the SPECT techniques is that these are the only commonly available direct methods of assessing viability, although the relatively low resolution of the images leaves them at a disadvantage for detecting small areas of MI. The common SPECT radiopharmaceuticals are also tracers of myocardial perfusion and the techniques thereby readily detect areas of MI and inducible perfusion abnormalities. ECG-gated imaging provides a reliable assessment of myocardial motion, thickening and global function. Evolving radionuclide techniques that are relevant to the assessment of MI include imaging of sympathetic innervation using iodine-123-labelled meta-iodo-benzylguanidine (mIBG),<sup>55</sup> imaging of matrix metalloproteinase activation in ventricular remodelling,<sup>56,57</sup> and refined assessment of myocardial metabolism.<sup>58</sup>

### Magnetic Resonance Imaging

The high tissue contrast of cardiovascular MRI provides an accurate assessment of myocardial function and it has similar

capability to echocardiography in suspected acute MI. Paramagnetic contrast agents can be used to assess myocardial perfusion and the increase in extracellular space that is associated with the fibrosis of prior MI. These techniques have been used in the setting of acute MI,<sup>59,60</sup> and imaging of myocardial fibrosis by delayed contrast enhancement is able to detect even small areas of subendocardial MI. It is also of value in detecting myocardial disease states that can mimic MI, such as myocarditis.<sup>61</sup>

### Computed Tomography

Infarcted myocardium is initially visible as a focal area of decreased left ventricle (LV) enhancement, but later imaging shows hyper-enhancement, as with late gadolinium imaging by MRI.<sup>62</sup> This finding is clinically relevant because contrast-enhanced CT may be performed for suspected pulmonary embolism and aortic dissection—conditions with clinical features that overlap with those of acute MI—but the technique is not used routinely. Similarly, CT assessment of myocardial perfusion is technically feasible but not yet fully validated.

### Applying Imaging in Acute Myocardial Infarction

Imaging techniques can be useful in the diagnosis of acute MI because of their ability to detect wall motion abnormalities or loss of viable myocardium in the presence of elevated cardiac biomarker values. If, for some reason, biomarkers have not been measured or may have normalized, demonstration of new loss of myocardial viability in the absence of non-ischaemic causes meets the criteria for MI. Normal function and viability have a very high negative predictive value and practically exclude acute MI.<sup>63</sup> Thus, imaging techniques are useful for early triage and discharge of patients with suspected MI. However, if biomarkers have been measured at appropriate times and are normal, this excludes an acute MI and takes precedence over the imaging criteria.

Abnormal regional myocardial motion and thickening may be caused by acute MI or by one or more of several other conditions, including prior MI, acute ischaemia, stunning or hibernation. Non-ischaemic conditions, such as cardiomyopathy and inflammatory or infiltrative diseases, can also lead to regional loss of viable myocardium or functional abnormality. Therefore, the positive predictive value of imaging for acute MI is not high unless these conditions can be excluded, and unless a new abnormality is detected or can be presumed to have arisen in the setting of other features of acute MI.

Echocardiography provides an assessment of many non-ischaemic causes of acute chest pain, such as peri-myocarditis, valvular heart disease, cardiomyopathy, pulmonary embolism or aortic dissection.<sup>53</sup> It is the imaging technique of choice for detecting complications of acute MI, including myocardial free wall rupture, acute ventricular septal defect, and mitral regurgitation secondary to papillary muscle rupture or ischaemia.

Radionuclide imaging can be used to assess the amount of myocardium that is salvaged by acute revascularization.<sup>64</sup> Tracer is injected at the time of presentation, with imaging deferred until after revascularization, providing a measure of myocardium at risk. Before discharge, a second resting

injection provides a measure of final infarct size, and the difference between the two corresponds to the myocardium that has been salvaged.

### Applying Imaging in Late Presentation of Myocardial Infarction

In case of late presentation after suspected MI, the presence of regional wall motion abnormality, thinning or scar in the absence of non-ischaemic causes, provides evidence of past MI. The high resolution and specificity of late gadolinium enhancement MRI for the detection of myocardial fibrosis has made this a very valuable technique. In particular, the ability to distinguish between subendocardial and other patterns of fibrosis provides a differentiation between ischaemic heart disease and other myocardial abnormalities. Imaging techniques are also useful for risk stratification after a definitive diagnosis of MI. The detection of residual or remote ischaemia and/or ventricular dysfunction provides powerful indicators of later outcome.

### Diagnostic Criteria for Myocardial Infarction With PCI (MI Type 4)

Balloon inflation during PCI often causes transient ischaemia, whether or not it is accompanied by chest pain or ST-T changes. Myocardial injury with necrosis may result from recognizable peri-procedural events—alone or in combination—such as coronary dissection, occlusion of a major coronary artery or a side-branch, disruption of collateral flow, slow flow or no-reflow, distal embolization, and microvascular plugging. Embolization of intracoronary thrombus or atherosclerotic particulate debris may not be preventable, despite current anticoagulant and antiplatelet adjunctive therapy, aspiration or protection devices. Such events induce inflammation of the myocardium surrounding islets of myocardial necrosis.<sup>65</sup> New areas of myocardial necrosis have been demonstrated by MRI following PCI.<sup>66</sup>

The occurrence of procedure-related myocardial cell injury with necrosis can be detected by measurement of cardiac biomarkers before the procedure, repeated 3–6 h later and, optionally, further re-measurement 12 h thereafter. Increasing levels can only be interpreted as procedure-related myocardial injury if the pre-procedural cTn value is normal ( $\leq 99$ th percentile URL) or if levels are stable or falling.<sup>67,68</sup> In patients with normal pre-procedural values, elevation of cardiac biomarker values above the 99th percentile URL following PCI are indicative of procedure-related myocardial injury. In earlier studies, increased values of post-procedural cardiac biomarkers, especially CKMB, were associated with impaired outcome.<sup>69,70</sup> However, when cTn concentrations are normal before PCI and become abnormal after the procedure, the threshold above the 99th percentile URL—whereby an adverse prognosis is evident—is not well defined<sup>71</sup> and it is debatable whether such a threshold even exists.<sup>72</sup> If a single baseline cTn value is elevated, it is impossible to determine whether further increases are due to the procedure or to the initial process causing the elevation. In this situation, it appears that the prognosis is largely determined by the pre-procedural cTn level.<sup>71</sup> These relationships will probably become even more complex for the new high-sensitivity troponin assays.<sup>70</sup>

In patients undergoing PCI with normal ( $\leq 99$ th percentile URL) baseline cTn concentrations, elevations of cTn  $> 5 \times 99$ th percentile URL occurring within 48 h of the procedure—plus either (i) evidence of prolonged ischaemia ( $\geq 20$  min) as demonstrated by prolonged chest pain, or (ii) ischaemic ST changes or new pathological Q waves, or (iii) angiographic evidence of a flow limiting complication, such as of loss of patency of a side branch, persistent slow-flow or no-reflow, embolization, or (iv) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality—is defined as PCI-related MI (type 4a). This threshold of cTn values  $\leq 5 \times 99$ th percentile URL is arbitrarily chosen, based on clinical judgement and societal implications of the label of peri-procedural MI. When a cTn value is  $\leq 5 \times 99$ th percentile URL after PCI and the cTn value was normal before the PCI—or when the cTn value is  $> 5 \times 99$ th percentile URL in the absence of ischaemic, angiographic or imaging findings—the term ‘myocardial injury’ should be used.

If the baseline cTn values are elevated and are stable or falling, then a rise of  $> 20\%$  is required for the diagnosis of a type 4a MI, as with reinfarction. Recent data suggest that, when PCI is delayed after MI until biomarker concentrations are falling or have normalized, and elevation of cardiac biomarker values then reoccurs, this may have some long-term significance. However, additional data are needed to confirm this finding.<sup>73</sup>

A subcategory of PCI-related MI is stent thrombosis, as documented by angiography and/or at autopsy and a rise and/or fall of cTn values  $\leq 99$ th percentile URL (identified as MI type 4b). In order to stratify the occurrence of stent thrombosis in relation to the timing of the PCI procedure, the Academic Research Consortium recommends temporal categories of ‘early’ (0 to 30 days), ‘late’ (31 days to 1 year), and ‘very late’ ( $> 1$  year) to distinguish likely differences in the contribution of the various pathophysiological processes during each of these intervals.<sup>74</sup> Occasionally, MI occurs in the clinical setting of what appears to be a stent thrombosis: however, at angiography, restenosis is observed without evidence of thrombus (see section on clinical trials).

### Diagnostic Criteria for Myocardial Infarction With CABG (MI Type 5)

During CABG, numerous factors can lead to periprocedural myocardial injury with necrosis. These include direct myocardial trauma from (i) suture placement or manipulation of the heart, (ii) coronary dissection, (iii) global or regional ischaemia related to inadequate intra-operative cardiac protection, (iv) microvascular events related to reperfusion, (v) myocardial injury induced by oxygen free radical generation, or (vi) failure to reperfuse areas of the myocardium that are not subtended by graftable vessels.<sup>75–77</sup> MRI studies suggest that most necrosis in this setting is not focal but diffuse and localized in the subendocardium.<sup>78</sup>

In patients with normal values before surgery, any increase of cardiac biomarker values after CABG indicates myocardial necrosis, implying that an increasing magnitude of biomarker concentrations is likely to be related to an impaired outcome. This has been demonstrated in clinical studies employing CKMB, where elevations 5, 10 and 20 times the URL after

CABG were associated with worsened prognosis; similarly, impaired outcome has been reported when cTn values were elevated to the highest quartile or quintile of the measurements.<sup>79–83</sup>

Unlike prognosis, scant literature exists concerning the use of biomarkers for defining an MI related to a primary vascular event in a graft or native vessel in the setting of CABG. In addition, when the baseline cTn value is elevated (>99th percentile URL), higher levels of biomarker values are seen post-CABG. Therefore, biomarkers cannot stand alone in diagnosing MI in this setting. In view of the adverse impact on survival observed in patients with significant elevation of biomarker concentrations, this Task Force suggests, by arbitrary convention, that cTn values >10×99th percentile URL during the first 48 h following CABG, occurring from a normal baseline cTn value (≤99th percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographically documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, should be considered as diagnostic of a CABG-related MI (type 5). Cardiac biomarker release is considerably higher after valve replacement with CABG than with bypass surgery alone, and with on-pump CABG compared to off-pump CABG.<sup>84</sup> The threshold described above is more robust for isolated on-pump CABG. As for PCI, the existing principles from the universal definition of MI should be applied for the definition of MI >48 h after surgery.

### Assessment of MI in Patients Undergoing Other Cardiac Procedures

New ST-T abnormalities are common in patients who undergo cardiac surgery. When new pathological Q waves appear in different territories than those identified before surgery, MI (types 1 or 2) should be considered, particularly if associated with elevated cardiac biomarker values, new wall motion abnormalities or haemodynamic instability.

Novel procedures such as transcatheter aortic valve implantation (TAVI) or mitral clip may cause myocardial injury with necrosis, both by direct trauma to the myocardium and by creating regional ischaemia from coronary obstruction or embolization. It is likely that, similarly to CABG, the more marked the elevation of the biomarker values, the worse the prognosis—but data on that are not available.

Modified criteria have been proposed for the diagnosis of periprocedural MI ≤72 h after aortic valve implantation.<sup>85</sup> However, given that there is too little evidence, it appears reasonable to apply the same criteria for procedure-related MI as stated above for CABG.

Ablation of arrhythmias involves controlled myocardial injury with necrosis, by application of warming or cooling of the tissue. The extent of the injury with necrosis can be assessed by cTn measurement: however, an elevation of cTn values in this context should not be labelled as MI.

### Myocardial Infarction Associated With Non-Cardiac Procedures

Perioperative MI is the **most common** major perioperative vascular complication in major non-cardiac surgery, and is

associated with a **poor prognosis**.<sup>86,87</sup> Most patients who have a perioperative MI will **not** experience **ischaemic symptoms**. Nevertheless, **asymptomatic** perioperative MI is **as strongly associated** with **30-day mortality**, as is **symptomatic** MI.<sup>86</sup> **Routine monitoring** of **cardiac biomarkers** in high-risk patients, both **prior** to and **48–72 h after** major surgery, is therefore recommended. Measurement of **high-sensitivity cTn** in post-operative samples reveals that **45%** of patients have levels **above** the **99th percentile URL** and **22%** have an **elevation** and a **rising** pattern of values indicative of **evolving myocardial necrosis**.<sup>88</sup> Studies of patients undergoing major non-cardiac surgery strongly support the idea that many of the infarctions diagnosed in this context are caused by a prolonged **imbalance** between myocardial oxygen **supply** and **demand**, against a **background** of **CAD**.<sup>89,90</sup> Together with a rise and/or fall of cTn values, this indicates MI **type 2**. However, **one** pathological **study** of fatal perioperative MI patients showed plaque **rupture** and platelet aggregation, leading to thrombus formation, in approximately **half** of such events;<sup>91</sup> that is to say, MI **type 1**. Given the differences that probably exist in the therapeutic approaches to each, close clinical scrutiny and judgement is needed.

### Myocardial Infarction in the Intensive Care Unit

**Elevations** of **cTn** values are **common** in patients in the intensive care unit and are associated with adverse **prognosis**, regardless of the underlying disease state.<sup>92,93</sup> Some elevations may reflect **MI type 2** due to underlying CAD and increased myocardial oxygen **demand**.<sup>94</sup> Other patients may have elevated values of cardiac biomarkers, due to myocardial **injury** with **necrosis** induced by **catecholamine** or **direct toxic** effect from **circulating toxins**. Moreover, in some patients, MI **type 1** may occur. It is often a challenge for the clinician, caring for a critically ill patient with severe single organ or multi-organ pathology, to decide on a plan of action when the patient has **elevated** cTn values. If and when the patient recovers from the critical illness, clinical judgement should be employed to decide whether—and to what extent—further evaluation for CAD or structural heart disease is indicated.<sup>95</sup>

### Recurrent Myocardial Infarction

'**Incident** MI' is defined as the individual's **first** MI. When features of MI occur in the **first 28** days after an incident event, this is not counted as a new event for epidemiological purposes. If characteristics of MI occur **after 28** days following an incident MI, it is considered to be a **recurrent** MI.<sup>3</sup>

### Reinfarction

The term 'reinfarction' is used for an acute MI that occurs **within 28** days of an incident- or recurrent MI.<sup>3</sup> The ECG diagnosis of suspected reinfarction following the initial MI may be confounded by the initial evolutionary ECG changes. Reinfarction should be considered when ST elevation ≥0.1 mV recurs, or new pathognomonic Q waves appear, in at least two contiguous leads, particularly when associated with ischaemic symptoms for 20 min or longer. Re-elevation of the ST-segment can, however, also be seen in threatened myocardial rupture and should lead to additional diagnostic workup. ST depression or LBBB alone are

non-specific findings and should not be used to diagnose reinfarction.

In patients in whom reinfarction is suspected from clinical signs or symptoms following the initial MI, an immediate measurement of cTn is recommended. A second sample should be obtained 3–6 h later. If the cTn concentration is elevated, but stable or decreasing at the time of suspected reinfarction, the diagnosis of reinfarction requires a 20% or greater increase of the cTn value in the second sample. If the initial cTn concentration is normal, the criteria for new acute MI apply.

### Myocardial Injury or Infarction Associated With Heart Failure

Depending on the assay used, detectable-to-clearly elevated cTn values, indicative of myocardial injury with necrosis, may be seen in patients with HF syndrome.<sup>96</sup> Using high-sensitivity cTn assays, measurable cTn concentrations may be present in nearly all patients with HF, with a significant percentage exceeding the 99th percentile URL, particularly in those with more severe HF syndrome, such as in acutely decompensated HF.<sup>97</sup>

Whilst MI type 1 is an important cause of acutely decompensated HF—and should always be considered in the context of an acute presentation—elevated cTn values alone, in a patient with HF syndrome, do not establish the diagnosis of MI type 1 and may, indeed, be seen in those with non-ischaemic HF. Beyond MI type 1, multiple mechanisms have been invoked to explain measurable-to-pathologically elevated cTn concentrations in patients with HF.<sup>96,97</sup> For example, MI type 2 may result from increased transmural pressure, small-vessel coronary obstruction, endothelial dysfunction, anaemia or hypotension. Besides MI type 1 or 2, cardiomyocyte apoptosis and autophagy due to wall stretch has been experimentally demonstrated. Direct cellular toxicity related to inflammation, circulating neurohormones, infiltrative processes, as well as myocarditis and stress cardiomyopathy, may present with HF and abnormal cTn measurement.<sup>97</sup>

Whilst prevalent and complicating the diagnosis of MI, the presence, magnitude and persistence of cTn elevation in HF is increasingly accepted to be an independent predictor of adverse outcomes in both acute and chronic HF syndrome, irrespective of mechanism, and should not be discarded as ‘false positive.’<sup>97,98</sup>

In the context of an acutely decompensated HF presentation, cTn I or T should always be promptly measured and ECG recorded, with the goal of identifying or excluding MI type 1 as the precipitant. In this setting, elevated cTn values should be interpreted with a high level of suspicion for MI type 1 if a significant rise and/or fall of the marker are seen, or if it is accompanied by ischaemic symptoms, new ischaemic ECG changes or loss of myocardial function on non-invasive testing. Coronary artery anatomy may often be well-known; such knowledge may be used to interpret abnormal troponin results. If normal coronary arteries are present, either a type 2 MI or a non-coronary mechanism for troponin release may be invoked.<sup>97</sup>

On the other hand, when coronary anatomy is not established, the recognition of a cTn value in excess of the 99th percentile URL alone is not sufficient to make a diagnosis of acute MI due to CAD, nor is it able to identify the mechanism

for the abnormal cTn value. In this setting, further information, such as myocardial perfusion studies, coronary angiography, or MRI is often required to better understand the cause of the abnormal cTn measurement. However, it may be difficult to establish the reason for cTn abnormalities, even after such investigations.<sup>96,97</sup>

### Application of MI in Clinical Trials and Quality Assurance Programmes

In clinical trials, MI may be an entry criterion or an end-point. A universal definition for MI is of great benefit for clinical studies, since it will allow a standardized approach for interpretation and comparison across different trials. The definition of MI as an entry criterion, e.g. MI type 1 and *not* MI type 2, will determine patient characteristics in the trial. Occasionally MI occurs and, at angiography, restenosis is the only angiographic explanation.<sup>99,100</sup> This PCI-related MI type might be designated as an ‘MI type 4c,’ defined as  $\geq 50\%$  stenosis at coronary angiography or a complex lesion associated with a rise and/or fall of cTn values  $>99$ th percentile URL and no other significant obstructive CAD of greater severity following: (i) initially successful stent deployment or (ii) dilatation of a coronary artery stenosis with balloon angioplasty ( $<50\%$ ).

In recent investigations, different MI definitions have been employed as trial outcomes, thereby hampering comparison and generalization between these trials. Consistency among investigators and regulatory authorities, with regard to the definition of MI used as an endpoint in clinical investigations, is of substantial value. Adaptation of the definition to an individual clinical study may be appropriate in some circumstances and should have a well-articulated rationale. No matter what, investigators should ensure that a trial provides comprehensive data for the various types of MI and includes the 99th percentile URL decision limits of cTn or other biomarkers employed. Multiples of the 99th percentiles URL may be indicated as shown in Table 6. This will facilitate comparison of trials and meta-analyses.

Because different assays may be used, including newer, higher-sensitivity cTn assays in large multicentre clinical trials, it is advisable to consistently apply the 99th percentile URL. This will not totally harmonize troponin values across different assays, but will improve the consistency of the results. In patients undergoing cardiac procedures, the incidence of MI may be used as a measure of quality, provided that a consistent definition is applied by all centres participating in the quality assurance programme. To be effective and to avoid bias, this type of assessment will need to develop a paradigm to harmonize the different cTn assay results across sites.

### Public Policy Implications of the Adjustment of the MI Definition

Revision of the definition of MI has a number of implications for individuals as well as for society at large. A tentative or final diagnosis is the basis for advice about further diagnostic testing, lifestyle changes, treatment and prognosis for the patient. The aggregate of patients with a particular diagnosis is the basis for health care planning and policy and resource allocation.

One of the goals of good clinical practice is to reach a definitive and specific diagnosis, which is supported by

**Table 6. Tabulation in Clinical Trials of MI Types According to Multiples of the 99th Percentile Upper Reference Limit of the Applied Cardiac Biomarker**

Multiples x99%	MI type 1 Spontaneous	MI type 2 Secondary	MI type 3 <sup>a</sup> Death	MI type 4a PCI	MI type 4b Stent-thrombus	MI type 4c <sup>b</sup> Restenosis	MI type 5 CABG
1–3							
3–5							
5–10							
>10							
Total							

MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.

<sup>a</sup>Biomarker values are unavailable because of death before blood samples are obtained (blue area).

Red areas indicate arbitrarily defined cTn values below the MI decision limit whether PCI or CABG.

<sup>b</sup>Restenosis is defined as  $\geq 50\%$  stenosis at coronary angiography or a complex lesion associated with a rise and/or fall of cTn values  $>99$ th percentile URL and no other significant obstructive CAD of greater severity following: (i) initially successful stent deployment or (ii) dilatation of a coronary artery stenosis with balloon angioplasty ( $<50\%$ ).

current scientific knowledge. The approach to the definition of MI outlined in this document meets this goal. In general, the conceptual meaning of the term ‘myocardial infarction’ has not changed, although new, sensitive diagnostic methods have been developed to diagnose this entity. Thus, the diagnosis of acute MI is a clinical diagnosis based on patient symptoms, ECG changes, and highly sensitive biochemical markers, as well as information gleaned from various imaging techniques. It is important to characterize the type of MI as well as the extent of the infarct, residual LV function, and the severity of CAD and other risk factors, rather than merely making a diagnosis of MI. The information conveyed about the patient’s prognosis and ability to work requires more than just the mere statement that the patient has suffered an MI. The many additional factors just mentioned are also required so that appropriate social, family, and employment decisions can be made. A number of risk scores have been developed to predict the prognosis after MI. The classification of the various other prognostic entities associated with MI should lead to a reconsideration of the clinical coding entities currently employed for patients with the myriad conditions that can lead to myocardial necrosis, with consequent elevation of biomarker values.

It should be appreciated that the current modification of the definition of MI may be associated with consequences for the patients and their families in respect of psychological status, life insurance, professional career, as well as driving- and pilots’ licences. The diagnosis is associated also with societal implications as to diagnosis-related coding, hospital reimbursement, public health statistics, sick leave, and disability attestation. In order to meet this challenge, physicians must be adequately informed of the altered diagnostic criteria. Educational materials will need to be created and treatment guidelines must be appropriately adapted. Professional societies and health-care planners should take steps to facilitate the rapid dissemination of the revised definition to physicians, other health care professionals, administrators, and the general public.

### Global Perspectives of the Definition of Myocardial Infarction

Cardiovascular disease is a global health problem. Understanding the burden and effects of CAD in populations is of

critical importance. Changing clinical definitions, criteria and biomarkers add challenges to our understanding and ability to improve the health of the public. The definition of MI for clinicians has important and immediate therapeutic implications. For epidemiologists, the data are usually retrospective, so consistent case definitions are critical for comparisons and trend analysis. The standards described in this report are suitable for epidemiology studies. However, to analyse trends over time, it is important to have consistent definitions and to quantify adjustments when biomarkers or other diagnostic criteria change.<sup>101</sup> For example, the advent of cTn dramatically increased the number of diagnosable MIs for epidemiologists.<sup>3,102</sup>

In countries with limited economic resources, cardiac biomarkers and imaging techniques may not be available except in a few centres, and even the option of ECG recordings may be lacking. In these surroundings, the WHO states that biomarker tests or other high-cost diagnostic testing are unfit for use as compulsory diagnostic criteria.<sup>3</sup> The WHO recommends the use of the ESC/ACCF/AHA/WHF Universal MI Definition in settings without resource constraints, but recommends more flexible standards in resource-constrained locations.<sup>3</sup>

Cultural, financial, structural and organisational problems in the different countries of the world in the diagnosis and therapy of acute MI will require ongoing investigation. It is essential that the gap between therapeutic and diagnostic advances be addressed in this expanding area of cardiovascular disease.

### Conflicts of Interest

The members of the Task Force of the ESC, the ACCF, the AHA and the WHF have participated independently in the preparation of this document, drawing on their academic and clinical experience and applying an objective and clinical examination of all available literature. Most have undertaken—and are undertaking—work in collaboration with industry and governmental or private health providers (research studies, teaching conferences, consultation), but all believe such activities have not influenced their judgement. The best guarantee of their independence is in the quality of their past

and current scientific work. However, to ensure openness, their relationships with industry, government and private health providers are published online as a [Data Supplement](#). Expenses for the Task Force/Writing Committee and preparation of this document were provided entirely by the above-mentioned joint associations.

### Acknowledgments

We are very grateful to the dedicated staff of the Practice Guidelines Department of the ESC.

### References

1. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined — A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Eur Heart J*. 2000;21:1502–1513; *J Am Coll Cardiol*. 2000; 36:959–969.
2. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J*. 2007;28:2525–2538; *Circulation*. 2007;116:2634–2653; *J Am Coll Cardiol*. 2007;50:2173–2195.
3. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Ngu Blackett K, Lisheng L and Writing group on behalf of the participating experts of the WHO consultation for revision of WHO definition of myocardial infarction: 2008–09 revision. *Int J Epidemiol*. 2011;40: 139–146.
4. Jennings RB, Ganote CE. Structural changes in myocardium during acute ischemia. *Circ Res*. 1974;35 Suppl 3:156–172.
5. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease. *J Am Coll Cardiol*. 2006;48:1–11.
6. White HD. Pathobiology of troponin elevations. *J Am Coll Cardiol*. 2011;57:2406–2408.
7. Jaffe AS. Chasing troponin: how low can you go if you can see the rise? *J Am Coll Cardiol*. 2006;48:1763–1764.
8. Apple FS, Jesse RL, Newby LK, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. *Circulation*. 2007;115:e352–e355.
9. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers of acute coronary syndromes. *Circulation*. 2007;115:e356–e375.
10. Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, Tubaro M, Alpert JS, Biasucci LM, Koenig W, Mueller C, Huber K, Hamm C, Jaffe AS; Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of cardiac troponin measurement in acute cardiac care. *Eur Heart J*. 2010;31:2197–2204.
11. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS; Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. How to use high-sensitivity cardiac troponins in acute cardiac care. *Eur Heart J*. 2012 Jun 21. [Epub ahead of print.]
12. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. *Clin Chem*. 2012;58:54–61.
13. Jaffe AS, Apple FS, Morrow DA, Lindahl B, Katus HA. Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the definition of myocardial infarction. *Clin Chem*. 2010;56:941–943.
14. MacRae AR, Kavsak PA, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, Yerna M-J, Jaffe AS. Assessing the requirement for the six-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. *Clin Chem*. 2006;52:812–818.
15. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA*. 2010;304: 2503–2512.
16. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E. Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery disease. *N Engl J Med*. 2009;361:2538–2547.
17. Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, Shah ASV, Paterson E, MacLeod M, Graham C, Walker S, Denvir MA, Fox KAA, Newby DE. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. *JAMA*. 2011;305:1210–1216.
18. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. *Circulation*. 2011;123:1367–1376.
19. Kavsak PA, Xu L, Yusuf S, McQueen MJ. High-sensitivity cardiac troponin I measurement for risk stratification in a stable high-risk population. *Clin Chem*. 2011;57:1146–1153.
20. Apple FS, Simpson PA, Murakami MM. Defining the serum 99th percentile in a normal reference population measured by a high-sensitivity cardiac troponin I assay. *Clin Biochem*. 2010;43:1034–1036.
21. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T Assay. *Clin Chem*. 2010;56:254–261.
22. Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. *Clin Chem*. 2003;49: 1331–1336.
23. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. The Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial Investigators. *Circulation*. 2000;102: 1101–1106.
24. Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. *Arch Intern Med*. 2006;166:1391–1395.
25. Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F, Pena-Sing I, Axel L, Attubato MJ, Yatskar L, Kalhorn RT, Wood DA, Lobach IV, Hochman JS. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. *Circulation*. 2011;124:1414–1425.
26. Bertrand ME, LaBlanche JM, Tilmant PY, Thieuleux FA, Delforge MR, Carre AG, Asseman P, Berzin B, Libersa C, Laurent JM. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. *Circulation*. 1982;65:1299–1306.
27. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation*. 2000;101:948–954.
28. Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial function predicts future development of coronary artery disease: a study on women with chest pain and normal angiograms. *Circulation*. 2004; 109:2518–2523.
29. Harris BM, Nageh T, Marsden JT, Thomas MR, Sherwood RA. Comparison of cardiac troponin T and I and CK-MB for the detection of minor myocardial damage during interventional cardiac procedures. *Ann Clin Biochem*. 2000;37:764–769.
30. Januzzi JL, Lewandrowski K, MacGillivray TE, Newell JB, Kathiresan S, Servoss SJ, Lee-Lewandrowski E. A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. *J Am Coll Cardiol*. 2002;39:1518–1523.
31. Holmvang L, Jurlander B, Rasmussen C, Thijs JJ, Grande P, Clemmensen P. Use of biochemical markers of infarction for diagnosing

- perioperative myocardial infarction and early graft occlusion after coronary artery bypass surgery. *Chest*. 2002;121:103–111.
32. Miller WL, Garratt KN, Burritt MF, Reeder GS, Jaffe AS. Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention. *Chest*. 2004;125:275–280.
  33. Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. *Circ Cardiovasc Interv*. 2010;3:602–610.
  34. Cavallini C, Verdecchia P, Savonitto S, Arraiz G, Violini R, Olivari Z, Rubartelli P, De Servi S, Plebani M, Steffenino G, Sbarzaglia P, Ardissino D; Italian Atherosclerosis, Thrombosis and Vascular Biology and Society for Invasive Cardiology-GISE Investigators. Prognostic value of isolated troponin I elevation after percutaneous coronary intervention. *Circ Cardiovasc Interv*. 2010;3:431–435.
  35. Prasad A Jr, Rihal CS, Lennon RJ, Singh M, Jaffe AS, Holmes DR Jr. Significance of periprocedural myonecrosis on outcomes following percutaneous coronary intervention. *Circ Cardiovasc Interv*. 2008;1:10–19.
  36. Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. *N Engl J Med*. 2003;348:933–940.
  37. Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions other than acute myocardial infarction. *N Engl J Med*. 2003;349:2128–2135.
  38. McFarlane PW. Age, sex, and the ST amplitude in health and disease. *J Electrocardiol*. 2001;34:S35–S41.
  39. Zimetbaum PJ, Krishnan S, Gold A, Carrozza JP II, Josephson ME. Usefulness of ST-segment elevation in lead III exceeding that of lead II for identifying the location of the totally occluded coronary artery in inferior wall myocardial infarction. *Am J Cardiol*. 1998;81:918–919.
  40. Engelen DJ, Gorgels AP, Cheriex EC, De Muinck ED, Ophuis AJO, Dassen WR, Vainer J, van Ommen VG, Wellens HJ. Value of the electrocardiogram in localizing the occlusion site in the left anterior descending coronary artery in acute anterior myocardial infarction. *J Am Coll Cardiol*. 1999;34:389–395.
  41. Matetzky S, Freimark D, Feinberg MS, Novikov I, Rath S, Rabinowitz B, Kaplinsky E, Hod H. Acute myocardial infarction with isolated ST-segment elevation in posterior chest leads V7–V9. Hidden ST-segment elevations revealing acute posterior infarction. *J Am Coll Cardiol*. 1999;34:748–753.
  42. Lopez-Sendon J, Coma-Canella I, Alcasena S, Seoane J, Gamallo C. Electrocardiographic findings in acute right ventricular infarction: sensitivity and specificity of electrocardiographic alterations in right precordial leads V4R, V3R, V1, V2 and V3. *J Am Coll Cardiol*. 1985;6:1273–1279.
  43. Bayes de Luna A, Wagner G, Birnbaum Y, Nikus K, Fiol M, Gorgels A, Cinca J, Clemmensen PM, Pahlm O, Sclarowsky S, Stern S, Wellens H. A new terminology for the left ventricular walls and for the location of myocardial infarcts that present Q wave based on the standard of cardiac magnetic resonance imaging. A statement for healthcare professionals from a Committee appointed by the International Society for Holter and Noninvasive Electrocardiography. *Circulation*. 2006;114:1755–1760.
  44. Sgarbossa EB, Pinsky SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, Califf RM, Wagner GS. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle branch block. *N Engl J Med*. 1996;334:481–487.
  45. Jain S, Ting HT, Bell M, Bjerke CM, Lennon RJ, Gersh BJ, Rihal CS, Prasad A. Utility of left bundle branch block as a diagnostic criterion for acute myocardial infarction. *Am J Cardiol*. 2011;107:1111–1116.
  46. Savage RM, Wagner GS, Ideker RE, Podolsky SA, Hackel DB. Correlation of postmortem anatomic findings with electrocardiographic changes in patients with myocardial infarction: retrospective study of patients with typical anterior and posterior infarcts. *Circulation*. 1977;55:279–285.
  47. Horan LG, Flowers NC, Johnson JC. Significance of the diagnostic Q wave of myocardial infarction. *Circulation*. 1971;43:428–436.
  48. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction. *Circulation*. 2009;120:2529–2540.
  49. Burgess DC, Hunt D, Zannino D, Williamson E, Davis TME, Laakso M, Kesaniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Eur Heart J*. 2010;31:92–99.
  50. Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction. *Ann Intern Med*. 2001;135:801–811.
  51. Toma M, Fu Y, Ezekowitz JA, McAlister FA, Westerhout CM, Granger C, Armstrong PW. Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. *Am Heart J*. 2010;160:671–677.
  52. Stillman AE, Oudkerk M, Bluemke D, Bremerich J, Esteves FP, Garcia EV, Gutberlet M, Hundley WG, Jerosch-Herold M, Kuijpers D, Kwong RK, Nagel E, Lerakis S, Oshinski J, Paul JF, Underwood R, Wintersperger BJ, Rees MR; North American Society of Cardiovascular Imaging; European Society of Cardiac Radiology. *Int J Cardiovasc Imaging*. 2011;27:7–24.
  53. Flachskampf FA, Schmid M, Rost C, Achenbach S, deMaria AN, Daniel WG. Cardiac imaging after myocardial infarction. *Eur Heart J*. 2011;32:272–283.
  54. Kaul S, Miller JG, Grayburn PA, Hashimoto S, Hibberd M, Holland MR, Houle HC, Klein AL, Knoll P, Lang RM, Lindner JR, McCulloch ML, Metz S, Mor-Avi V, Pearlman AS, Pellikka PA, DeMars Plambeck N, Prater D, Porter TR, Sahn DJ, Thomas JD, Thomenius KE, Weissman NJ. A suggested roadmap for cardiovascular ultrasound research for the future. *J Am Soc Echocardiogr*. 2011;24:455–464.
  55. Carrio I, Cowie MR, Yamazaki J, Udelsion J, Camici PG. Cardiac sympathetic imaging with mIBG in heart failure. *J Am Coll Cardiol Imaging*. 2010;3:92–100.
  56. Narendorf M, Sosnovik DE, French BA, Swirski FK, Bengel F, Sadeghi MM, Lindner JR, Wu JC, Kraitchman DL, Fayad ZA, Sinusas AJ. Multimodality cardiovascular molecular imaging, Part II. *Circ Cardiovasc Imaging*. 2009;2:56–70.
  57. Kramer CM, Sinusas AJ, Sosnovik DE, French BA, Bengel FM. Multimodality imaging of myocardial injury and remodelling. *J Nucl Med*. 2010;51:p1075–1215.
  58. Taegtmeyer H. Tracing cardiac metabolism in vivo: one substrate at a time. *J Nucl Med*. 2010;51:80S–87S.
  59. Kim HW, Faraneh-Far A, Kim RJ. Cardiovascular magnetic resonance in patients with myocardial infarction. *J Am Coll Cardiol*. 2010;55:1–16.
  60. Beek AM, van Rossum AC. Cardiovascular magnetic resonance imaging in patients with acute myocardial infarction. *Heart*. 2010;96:237–243.
  61. Assomull RG, Lyne JC, Keenan N, Gulati A, Bunce NH, Davies SW, Pennell DJ, Prasad SK. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. *Eur Heart J*. 2007;28:1242–1249.
  62. Schuleri KH, George RT, Lardo AC. Assessment of coronary blood flow with computed tomography and magnetic resonance imaging. *J Nucl Cardiol*. 2010;17:582–590.
  63. Amsterdam EA, Kirk JD, Bluemke DA, Diercks D, Farkouh ME, Garvey JL, Kontos MC, McCord J, Miller TD, Morise A, Newby LK, Ruberg FL, Scordo KA, Thompson PD. Testing of low-risk patients presenting to the emergency department with chest pain. *Circulation*. 2010;122:1756–1776.
  64. Gibbons RJ, Valeti US, Araoz PA, Jaffe AS. The quantification of infarct size. *J Am Coll Cardiol*. 2004;44:1533–1542.
  65. Herrman J. Peri-procedural myocardial injury: 2005 update. *Eur Heart J*. 2005;26:2493–2519.
  66. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. *Circulation*. 2005;111:1027–1032.
  67. Gustavsson CG, Hansen O, Frennby B. Troponin must be measured before and after PCI to diagnose procedure-related myocardial injury. *Scand Cardiovasc J*. 2004;38:75–79.
  68. Miller WL, Garratt KN, Burritt MF, Lennon RJ, Reeder GS, Jaffe AS. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. *Eur Heart J*. 2006;27:1061–1069.
  69. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM. Myonecrosis after revascularization procedures. *J Am Coll Cardiol*. 1998;31:241–251.

70. White HD. The prequel. Defining prognostically important criteria in the periprocedural PCI troponin saga. *Circ Cardiovasc Interv.* 2012;5:142–145.
71. Jaffe AS, Apple FS, Lindahl B, Mueller C, Katus HA. Why all the struggle about CK-MB and PCI? *Eur Heart J.* 2012;33:1046–1048.
72. Damman P, Wallentin L, Fox KA, Windhausen F, Hirsch A, Clayton T, Pocock SJ, Lagerqvist B, Tijssen JG, de Winter RJ. Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: A collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR). *Circulation.* 2012;125:568–576.
73. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). *Circulation.* 2012;125:577–583.
74. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation.* 2007;115:2344–2351.
75. Benoit MO, Paris M, Sillera J, Fiemeyer A, Moatti N. Cardiac troponin I: Its contribution to the diagnosis of perioperative myocardial infarction and various complications of cardiac surgery. *Crit Care Med.* 2001;29:1880–1886.
76. Kovacevic R, Majkic-Singh N, Ignjatovic S, Otasevic P, Obrenovic R, Paris M, Vilotijevic B, Guermonprez JL. Troponin T levels in detection of perioperative myocardial infarction after coronary artery bypass surgery. *Clin Lab.* 2004;50:437–445.
77. Noora J, Ricci C, Hastings D, Hills S, Cybulsky I. Determination of Troponin I release after CABG surgery. *J Card Surg.* 2005;20:129–135.
78. Selvanayagam JB, Pigott D, Balacumaraswami L, Petersen SE, Neubauer S, Taggart DP. Relationship of irreversible myocardial injury to troponin I and creatine kinase-MB elevation after coronary artery bypass surgery: insights from cardiovascular magnetic resonance imaging. *J Am Coll Cardiol.* 2005;45:629–631.
79. Costa MA, Carere RG, Lichtenstein SV, Foley DP, de Valk V, Lindenboom W, Roose PCH, van Geldorp TR, Macaya C, Castanon JL, Fernandez-Aviles F, Gonzales JH, Heyer G, Unger F, Serruys PW. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). *Circulation.* 2001;104:2689–2693.
80. Klatte K, Chaitman BR, Theroux P, Gavard JA, Stocke K, Boyce S, Bartels C, Keller B, Jessel A. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release. *J Am Coll Cardiol.* 2001;38:1070–1077.
81. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. *J Am Coll Cardiol.* 2002;40:1961–1967.
82. Domanski M, Mahaffey K, Hasselblad V, Brener SJ, Smith PK, Hillis G, Engoren M, Alexander JH, Levy JH, Chaitman BR, Broderick S, Mack MJ, Pieper KS, Farkouh ME. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. *JAMA.* 2011;305:585–589.
83. Croal BL, Hillis GS, Gibson PH, Fazal MT, El-Shafei H, Gibson G, Jeffrey RR, Buchan KG, West D, Cuthbertson BH. Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. *Circulation.* 2006;114:1468–1475.
84. Selvanayagam JB, Petersen SE, Francis JM, Robson MD, Kardos A, Neubauer S, Taggart DP. Effects of off-pump versus on-pump coronary surgery on reversible and irreversible myocardial injury: a randomized trial using cardiovascular magnetic resonance imaging and biochemical markers. *Circulation.* 2004;109:345–350.
85. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. *Eur Heart J.* 2011;32:205–217; *J Am Coll Cardiol.* 2011;57:253–269.
86. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, Leslie K, Rao-Melacini P, Chrolavicius S, Yang H, Macdonald C, Avezum A, Lanthier L, Hu W, Yusuf S; POISE (PeriOperative ISchemic Evaluation) Investigators. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. *Ann Intern Med.* 2011;154:523–528.
87. The Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. *JAMA.* 2012;307:2295–2304.
88. Kavsak PA, Walsh M, Srinathan S, Thorlacius L, Buse GL, Botto F, Pettit S, McQueen MJ, Hill SA, Thomas S, Mrkobrada M, Alonso-Coello P, Berwanger O, Biccari BM, Cembrowski G, Chan MT, Chow CK, de Miguel A, Garcia M, Graham MM, Jacka MJ, Kueh JH, Li SC, Lit LC, Martinez-Bru C, Naidoo P, Nagele P, Pearse RM, Rodseth RN, Sessler DI, Sigamani A, Szczeklik W, Tiboni M, Villar JC, Wang CY, Xavier D, Devereaux PJ. High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: a prospective cohort study. *Clin Biochem.* 2011;44:1021–1024.
89. Fleisher LA, Nelson AH, Rosenbaum SH. Postoperative myocardial ischemia: etiology of cardiac morbidity or manifestation of underlying disease? *J Clin Anesth.* 1995;7:97–102.
90. Landesberg G, Mosseri M, Shatz V, Akopnik I, Bocher M, Mayer M, Anner H, Berlatzky Y, Weissman C. Cardiac troponin after major vascular surgery: The role of perioperative ischemia, preoperative thallium scanning, and coronary revascularization. *J Am Coll Cardiol.* 2004;44:569–575.
91. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. *Cardiovasc Pathol.* 1999;8:133–139.
92. Guest TM, Ramanathan AV, Tuteur PG, Schechtman KB, Ladenson JH, Jaffe AS. Myocardial injury in critically ill medical patients: A surprisingly frequent complication. *JAMA.* 1995;273:1945–1949.
93. Babuin L, Vasile VC, Rio Perez JA, Alegria JR, Chai HS, Afessa B, Jaffe AS. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. *Crit Care Med.* 2008;36:759–765.
94. Landesberg G, Vesselov Y, Einav S, Goodman S, Sprung CL, Weissman C. Myocardial ischemia, cardiac troponin, and long-term survival of high-cardiac risk critically ill intensive care unit patients. *Crit Care Med.* 2005;33:1281–1287.
95. Thygesen K, Alpert JS, Jaffe AS, White HD. Diagnostic application of the universal definition of myocardial infarction in the intensive care unit. *Curr Opin Crit Care.* 2008;14:543–548.
96. Kociol RD, Pang PS, Gheorghiane M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. *J Am Coll Cardiol.* 2010;56:1071–1078.
97. Januzzi JL Jr, Filippatos G, Nieminen M, Gheorghiane M, on Behalf of the Third Universal Task Force for the Definition of Myocardial Infarction: Heart Failure Section. Troponin elevation in patients with heart failure. *Eur Heart J.* 2012, Jun 28. [Epub ahead of print.]
98. Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. *J Am Coll Cardiol.* 2009;54:1715–1721.
99. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting era. *J Am Coll Cardiol.* 2010;56:1897–1907.
100. White HD, Reynolds HR, Carvalho AC, Pearte CA, Liu L, Martin CE, Knatterud GL, Dzavik V, Kruk M, Steg PG, Cantor WJ, Menon V, Lamas GA, Hochman JS. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. *Am Heart J.* 2012;163:563–571.
101. Rosamond W, Chambless L, Heiss G, Mosley T, Coresh J, Whitsel E, Wagenknecht L, Ni H, Folsom A. Twenty-two year trends in incidence of myocardial infarction, CHD mortality, and case-fatality in four US communities, 1987 to 2008. *Circulation.* 2012;125:1848–1857.
102. Luepker R, Duval S, Jacobs D, Smith L, Berger A. The effect of changing diagnostic algorithms on acute myocardial infarction rates. *Ann Epidemiology.* 2011;21:824–829.

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Alpert Joseph	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2010-2011)</li> <li>- Daiichi Sankyo : anticoagulation (2011)</li> <li>- Johnson &amp; Johnson : Anticoagulation (2010-2011)</li> <li>- Sanofi Aventis : Atrial fibrillation (2010-2011)</li> <li>- Servier : Drugs to reduce heart rate (2010-2011)</li> <li>- Novartis : Therapy of cardiovascular disease in geriatric patients (2011)</li> <li>- Novartis : Therapy of cardiovascular disease in geriatric patients (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation (2010)</li> <li>- Genzyme : Therapy of Gaucher's disease (2010)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2011)</li> <li>- Genzyme : Therapy of Gaucher's disease (2011)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Duke University : Data safety and monitoring committee for clinical trials, member and chair (2010)</li> <li>- Duke University : Data safety and monitoring committee for clinical trials, member and chair (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- TIMI group : Consultant and steering committee member on some of their randomized, double-blind clinical trials (2010)</li> <li>- TIMI group : Consultant and steering committee member on some of their randomized, double-blind clinical trials (2011)</li> </ul>
Antman Elliott	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : enoxaparin (2010)</li> <li>- As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : multiple (2010)</li> <li>- Eli Lilly : prasugrel (2010)</li> <li>- Daiichi Sankyo : prasugrel, edoxaban (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Antman Elliott	<ul style="list-style-type: none"> <li>- Sanofi Aventis : enoxaparin (2011)</li> <li>- As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : multiple (2011)</li> <li>- Eli Lilly : prasugrel (2011)</li> <li>- Daiichi Sankyo : prasugrel, edoxaban (2011)</li> </ul>
Apple Fred	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Instrumentation Laboratory : biomarkers (2010-2011)</li> <li>- OrthoClinical Diagnostics : biomarkers (2010-2011)</li> <li>- Abbott Laboratories : biomarkers (2010-2011)</li> <li>- Alere : biomarkers (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- BRAHMS GmbH : biomarkers (2010)</li> <li>- Siemens Healthcare : biomarkers (2010)</li> <li>- OrthoClinical Diagnostics : biomarkers (2010)</li> <li>- Abbott Laboratories : biomarkers (2010)</li> <li>- Roche Pharma : biomarkers (2010)</li> <li>- Alere : biomarkers (2010)</li> <li>- Radiometer : biomarkers (2010)</li> <li>- BioRad : biomarkers (2010)</li> <li>- Diagenics : biomarkers (2010)</li> <li>- Response Biomedical : biomarkers (2010)</li> <li>- BRAHMS GmbH : biomarkers (2011)</li> <li>- Siemens Healthcare : biomarkers (2011)</li> <li>- OrthoClinical Diagnostics : biomarkers (2011)</li> <li>- Abbott Laboratories : biomarkers (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Apple Fred	<ul style="list-style-type: none"> <li>- Roche Pharma : biomarkers (2011)</li> <li>- Alere : biomarkers (2011)</li> <li>- Radiometer : biomarkers (2011)</li> <li>- BioRad : biomarkers (2011)</li> <li>- Diagenics : biomarkers (2011)</li> <li>- Response Biomedical : biomarkers (2011)</li> </ul>
Armstrong Paul Wayne	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Advisor (2010)</li> <li>- Takeda Pharmaceuticals : Advisor (2010)</li> <li>- F. Hoffman La Roche Ltd : ALECARDIO (2010-2011)</li> <li>- Bristol Myers Squibb : APPRAISE-2 (2010)</li> <li>- Regado Biosciences : Medical Advisory Board (2010-2011)</li> <li>- Sanofi Aventis : New Concepts in Acute Coronary Syndromes: Beyond 2000 (XVI) (2010)</li> <li>- Bristol Myers Squibb : New Concepts in Acute Coronary Syndromes: Beyond 2000 (XVI) (2010)</li> <li>- Merck Sharp &amp; Dohme : New Concepts in Acute Coronary Syndromes: Beyond 2000 (XVI) (2010)</li> <li>- AstraZeneca and Eli Lilly : New Concepts in Acute Coronary Syndromes: Beyond 2012 (XVIII) (2011)</li> <li>- Regado Biosciences : RADAR (2010)</li> <li>- GlaxoSmithKline : SOLSTICE (2010)</li> <li>- Merck Sharp &amp; Dohme : TECOS (2010)</li> <li>- Merck &amp; Co. Inc. : TECOS (2011)</li> <li>- Merck Sharp &amp; Dohme Corp in conjunction with Duke Clinical Research Center : Thrombin Receptor Antagonist for Clinical Events Reduction Trial (TRACER) (2010)</li> <li>- Merck Sharp &amp; Company Inc. in conjunction with Duke Clinical Research Center : Thrombin Receptor Antagonist for Clinical Events Reduction Trial (TRACER) (2011)</li> <li>- Eli Lilly : TRILOGY (2010)</li> <li>- Eli Lilly/DCRI : TRILOGY (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Armstrong Paul Wayne	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Scios Inc, Ortho-Biotech, Johnson &amp; Johnson and Jansen Ortho Inc in conjunction with Duke Clinical Research Institute : ASCEND-HF (2010)</li> <li>- Merck Sharp &amp; Dohme Corp in conjunction with Duke Clinical Research Institute : IMPROVE IT (2010)</li> <li>- Portola Pharmaceuticals : INNOVATE-PCI (2010)</li> <li>- AstraZeneca in conjunction with Uppsala Clinical Research Centre : PLATO (2010)</li> <li>- Regado Biosciences : RADAR (2010)</li> <li>- GlaxoSmithKline : STABILITY (2010)</li> <li>- Boehringer Ingelheim, Hoffmann La Roche &amp; sanofiaventis Canada Inc in conjunction with Leuven Coordinating Centre : STREAM (2010)</li> <li>- Sanofi Aventis : STREAM Canadian substudy (2010)</li> <li>- Merck Sharp &amp; Dohme : TECOS (2010)</li> <li>- Merck Sharp &amp; Dohme Corp in conjunctin with Duke Clinical Research Center : TRACER (2010)</li> <li>- Scios Inc, Ortho-Biotech, Johnson &amp; Johnson and Jansen Ortho Inc in conjunction with Duke Clinical Research Institute : ASCEND-HF (2011)</li> <li>- Merck Sharp &amp; Dohme Corp in conjunction with Duke Clinical Research Institute : IMPROVE IT (2011)</li> <li>- GlaxoSmithKline : STABILITY (2011)</li> <li>- Boehringer Ingelheim, Hoffmann La Roche &amp; sanofiaventis Canada Inc in conjunction with Leuven Coordinating Centre : STREAM (2011)</li> <li>- Sanofi Aventis : STREAM Canadian substudy (2011)</li> <li>- Merck &amp; Co. Inc. : TECOS (2011)</li> <li>- Merck Sharp &amp; Dohme Corp in conjunctin with Duke Clinical Research Center : TRACER (2011)</li> </ul>
Atar Dan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiarrhythmic drug development (2010-2011)</li> <li>- Sanofi Aventis : Antiarrhythmic drugs (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : Antiarrhythmic drugs (2010-2011)</li> <li>- Sequel Pharmaceuticals : Antiarrhythmic treatment in Atrial Fibrillation (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Atar Dan	<ul style="list-style-type: none"> <li>- Bayer : anticoagulants (2010-2011)</li> <li>- Boehringer-Ingelheim : Anticoagulants (2010-2011)</li> <li>- BMS/Pfizer : anticoagulants (2010-2011)</li> <li>- Pfizer : Cholesterol lowering (2010-2011)</li> <li>- Novartis : neurohumoral inhibition / blood pressure lowering (2010-2011)</li> <li>- Astra Zeneca : Platelet inhibition (2010-2011)</li> <li>- BMS : Prevention of Reperfusion Injury in STEMI (2010-2011)</li> <li>- Kai Pharmaceuticals : Prevention of Reperfusion Injury in STEMI (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : anti-anginal medication (2010)</li> <li>- Population Research Institute, McMaster, Hamilton, Canada : Antiarrhythmic Therapy (2010)</li> <li>- TIMI group : anticoagulants (2010)</li> <li>- Duke Research Unit : Heart Failure Therapy (2010)</li> <li>- Servier : anti-anginal medication (2011)</li> <li>- Population Research Institute, McMaster, Hamilton, Canada : Antiarrhythmic Therapy (2011)</li> <li>- TIMI group : anticoagulants (2011)</li> <li>- Duke Research Unit : Heart Failure Therapy (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- EU-FP-7 grant / Trophos, Marseille : Prevention of Reperfusion Injury in STEMI (Leader of Clinical Research Consortium) (2010)</li> <li>- EU-FP-7 grant / Trophos, Marseille : Prevention of Reperfusion Injury in STEMI (Leader of Clinical Research Consortium) (2011)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Pronova Bioscience : Omega-3 and Platelet Function (2010)</li> </ul>
Bassand Jean-Pierre	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : clopidogrel, enoxaparin (2010-2011)</li> <li>- GlaxoSmithKline : fondaparinux (2010-2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Bassand Jean-Pierre	<ul style="list-style-type: none"> <li>- Lilly : prasugrel (2010-2011)</li> <li>- Bayer Healthcare : rivaroxaban (2010-2011)</li> <li>- Astra Zeneca : ticagrelor (2010-2011)</li> <li>- Iroko Cardio : Tirofiban (2010-2011)</li> </ul>
Bax Jeroen	<ul style="list-style-type: none"> <li>- Heart.org : Education (2010)</li> <li>- Astra Zeneca : Farma (2010)</li> <li>- Servier : Farma (2010)</li> <li>- Philips : Imaging (2010)</li> <li>- GE Healthcare : Imaging (2010)</li> <li>- Lantheus Inc : Imaging (2010)</li> <li>- Boston Scientific : Pacing (2010)</li> <li>- Medtronic : Pacing (2010)</li> <li>- St Jude Medical : Pacing (2010)</li> <li>- Biotronik : Pacing (2010)</li> <li>- Impulse Dynamics : Pacing (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2010)</li> <li>- Edwards Lifesciences : Heart Valves (2010)</li> <li>- GE Healthcare : Imaging (2010)</li> <li>- Lantheus Inc : Imaging (2010)</li> <li>- Boston Scientific : Pacing (2010)</li> <li>- Medtronic : Pacing (2010)</li> <li>- St Jude Medical : Pacing (2010)</li> <li>- Biotronik : Pacing (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Bax Jeroen	<ul style="list-style-type: none"> <li>- Servier : Farma (2011)</li> <li>- Edwards Lifesciences : Heart Valves (2011)</li> <li>- GE Healthcare : Imaging (2011)</li> <li>- Lantheus Inc : Imaging (2011)</li> <li>- Boston Scientific : Pacing (2011)</li> <li>- Medtronic : Pacing (2011)</li> <li>- St Jude Medical : Pacing (2011)</li> <li>- Biotronik : Pacing (2011)</li> </ul>
Bonow Robert	<ul style="list-style-type: none"> <li>- Edwards Lifesciences : Transcatheter heart valve technology (2010)</li> </ul>
Bove Alfred A	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Health System Networks, Inc : Biometric hardware systems (2011)</li> <li>- Health Station Networks, Inc : Non-invasive health monitoring (2010)</li> <li>- Insight Telehealth Systems, : Telemedicine (2010)</li> <li>- Insight Telehealth Systems, LLC : Telemedicine systems (2011)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Diving Medicine (2010)</li> <li>- Elsevier Sciences, Inc : Textbook author: Diving Medicine (2011)</li> </ul>
Chaitman Bernard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Gilead : antiangina therapy (2010-2011)</li> <li>- Takeda Pharmaceuticals : Antianginal therapy (2011)</li> <li>- Pfizer : dementia (2010-2011)</li> <li>- Lilly : Dementia drug (2010)</li> <li>- Merck Sharp &amp; Dohme : Lipid lowering (2010)</li> <li>- Roche Pharma : lipid lowering therapy (2010)</li> <li>- Roche Pharma : lipid lowering therapy (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Chaitman Bernard	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Lipid lowering, anti-inflammatory (2011)</li> </ul>
Clemmensen Peter Michael	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anti-Patelets (2011)</li> <li>- Daiichi Sankyo : Anti-platelets (2010)</li> <li>- Eli Lilly : Anti-platelets (2010-2011)</li> <li>- Evolva : Anti-platelets (2010-2011)</li> <li>- Bayer Healthcare : Antithrombotics (2010-2011)</li> <li>- Medicines Company : Antithrombotics (2010-2011)</li> <li>- Boehringer-Ingelheim : Diabetes and Antithrombotics (2010-2011)</li> <li>- Medtronic : Ischemia Monitoring (2010-2011)</li> <li>- Servier : Ischemic Heart Disease (2010-2011)</li> <li>- Pfizer : Lipids (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : Lipids (2010-2011)</li> <li>- Astra Zeneca : Lipids and ACS (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Antiplatelets (2010)</li> <li>- Eli Lilly : Antiplatelets (2010)</li> <li>- Medicines Company : Antithrombotics (2010)</li> <li>- F. Hoffman La Roche Ltd : Diabetes (2010)</li> <li>- Servier : Ischemic Heart Disease (2010)</li> <li>- Daiichi Sankyo : Antiplatelets (2011)</li> <li>- Eli Lilly : Antiplatelets (2011)</li> <li>- Medicines Company : Antithrombotics (2011)</li> <li>- F. Hoffman La Roche Ltd : Diabetes (2011)</li> <li>- Servier : Ischemic Heart Disease (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Filippatos Gerasimos	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Torrent : Heart failure (2010)</li> <li>- Vifor International : Heart failure (2010)</li> <li>- Corthera, Novartis : Heart failure (2010)</li> <li>- Bayer : Heart failure (2011)</li> <li>- Torrent : Heart failure (2011)</li> <li>- Vifor International : Heart failure (2011)</li> <li>- Corthera, Novartis : Heart failure (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- BRAHMS GmbH : Biomarkers (2010)</li> <li>- Roche Pharma : Biomarkers (2010)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Nanosphere : Biomarkers (2010)</li> <li>- European Union : Heart failure (2010)</li> <li>- Nanosphere : Biomarkers (2011)</li> <li>- European Union : Heart failure (2011)</li> </ul>
Fortmann Stephen	None
Fox Keith	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : ACS (2011)</li> <li>- Bayer : Atrial fibrillation (2011)</li> <li>- Duke University : atrial fibrillation (2010)</li> <li>- Duke University : Atrial Fibrillation and anti-thrombotic therapy (2011)</li> <li>- Astra Zeneca : coronary disease (2010)</li> <li>- Boehringer-Ingelheim : coronary disease (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Fox Keith	<ul style="list-style-type: none"> <li>- As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : coronary disease (2010)</li> <li>- TIMI group : Studies of thrombosis in coronary disease (2011)</li> <li>- Boehringer-Ingelheim : Thrombosis, Atrial fibrillation (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : anti-platelet therapy (2010)</li> <li>- Bayer : atrail fibrillation (2010)</li> <li>- Lilly : anti-thrombotic therapy (2011)</li> <li>- Bayer : atrial fibrillation (2011)</li> </ul>
Galvani Marcello	None
Gheorghide Mihai	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Heart Failure New Experimental (2011)</li> <li>- Bayer Schering Pharma : Heart Failure New Experimental (2011)</li> <li>- Sigma Tau : Heart Failure New Experimental (2011)</li> <li>- Johnson &amp; Johnson : New Experimental (2010)</li> <li>- Bayer Schering Pharma : New experimental (2010)</li> <li>- Sigma Tau : New Experimental (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : New Experimental (2010)</li> <li>- Medtronic : Heart Failure (2011)</li> <li>- Novartis : Heart Failure New Experimental (2011)</li> <li>- Cardioentis : Heart Failure New Experimental (2011)</li> <li>- Takeda Pharmaceuticals : Heart Failure New Experimental (2011)</li> </ul>
Gibbons Raymond J	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lantheus Inc : imaging (2010)</li> <li>- Molecular Insight Pharmaceuticals : imaging (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Gibbons Raymond J	- Lantheus Inc : Radionuclide Imaging (2011)
Gurfinkel Enrique Pablo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Thrombosis (2010)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bristol Myers Squibb : Thrombosis (2010)</p> <p>D - Research funding (departmental or institutional). - Institutional : Atherosclerosis (2010)</p>
Hamm Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : drugs (2010-2011)</li> <li>- Pfizer : drugs (2010-2011)</li> <li>- Sanofi Aventis : drugs (2010-2011)</li> <li>- GlaxoSmithKline : drugs (2010-2011)</li> <li>- Menarini : drugs (2010-2011)</li> <li>- Berlin Chemie AG : drugs (2010-2011)</li> <li>- Heart.org : drugs (2010-2011)</li> <li>- Medicines Company : drugs (2010-2011)</li> <li>- Boehringer Ingelheim - Ingelheim; Daiichi-Sankyo/Eli Lilly; Nycomed Pharma : drugs (2010-2011)</li> <li>- Takeda Pharmaceuticals : drugs (2010-2011)</li> <li>- Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier : drugs (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : drugs (2010-2011)</li> <li>- BRAHMS GmbH : markers (2010-2011)</li> <li>- Siemens Healthcare : MRI (2010-2011)</li> <li>- Boston Scientific : PCI (2010-2011)</li> <li>- Cordis and Medtronic : PCI (2010-2011)</li> </ul>
Hod Hanoch	- Sanofi Aventis : Israeli PI in TAO trial (2010)

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Hu Dayi	None
Jaffe Allan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : biomarkers (2010)</li> <li>- Pfizer : biomarkers (2010)</li> <li>- Beckman Coulter : biomarkers (2010)</li> <li>- Roche Pharma : biomarkers (2010)</li> <li>- Alere : biomarkers (2010)</li> <li>- Critical Diagnostics : biomarkers (2010)</li> <li>- Tethys Bioscience : biomarkers (2010)</li> <li>- Critical Diagnostics : ST2 (2011)</li> <li>- Amgen : troponin (2011)</li> <li>- Beckman Coulter : troponin (2011)</li> <li>- Abbott Laboratories : troponin (2011)</li> <li>- Alere : troponin (2011)</li> <li>- Radiometer : troponin (2011)</li> <li>- Roche Diagnostics : troponin (2011)</li> <li>- Theheart.org : troponin (2011)</li> <li>- OrthoClinical Diagnostics : troponin + other analytes (2011)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Beckman Coulter : biomarkers (2010)</li> </ul>
Januzzi James	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Pharma : biomarkers (2010-2011)</li> <li>- Critical Diagnostics : biomarkers (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : Biomarkers (2010)</li> <li>- Roche Pharma : biomarkers (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Januzzi James	<ul style="list-style-type: none"> <li>- Critical Diagnostics : Biomarkers (2010)</li> <li>- BRAHMS GmbH : Biomarkers (2011)</li> <li>- Siemens Healthcare : Biomarkers (2011)</li> <li>- Roche Pharma : biomarkers (2011)</li> </ul>
Johanson Per	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary care (2010-2011)</li> <li>- Medicines Company : acute coronary care (2010)</li> <li>- Astra Zeneca : ACS (2011)</li> <li>- Lilly : ACS (2011)</li> </ul>
Katus Hugo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca; Bayer; Daiichi Sankyo; Roche Diagnostics, Menarini, : Ticagrelor, Rivaroxaban, Prasugrel, Troponin T, Ranolazine (2011)</li> <li>- Astra Zeneca; Bayer; Daiichi Sankyo; Roche Diagnostics; Menarini; : Ticagrelor, Rivaroxaban, Prasugrel, TroponinT, Ranolazine (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca, Bayer AG, Daiichi-Sankyo, MSD, Novartis, Sanofi-Aventis, Servie, Menarini, Roche Diagnostics, Abbott : Rivaroxaban, Ticagrelor, Prasugrel, Ranexa, Rasilez, (2010)</li> <li>- Astra Zeneca, Bayer Ag, Daiichi Sankyo, MSD, Novartis, Sanofi-Aventis, Servier, Roche Diagnostics : Rivaroxaban, Ticagrelor, Prasugrel, Ranexa, Rasilez (2011)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Roche Pharma : Troponin T (2010)</li> <li>- Roche Pharma : Troponin T (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott; Medtronic; St Jude; Biotronik; : Investiagtor Initiated Trials; Clinical registries (2010)</li> <li>- Abbott, Medtronic, St. Jude, Biotronik : Investigator Initiated Trials, Clinical registries (2011)</li> </ul>
Levy Daniel	None
Lindahl Bertil	<ul style="list-style-type: none"> <li>- Philips : Scientific advisory board for biomarkers (2010-2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Lindahl Bertil	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Pharma : medical advisor for clinical study (2010)</li> <li>- bioMérieux S.A : medical advisor for clinical study (2011)</li> <li>- Roche Pharma : medical advisor for clinical study and scientific advisory board (2011)</li> <li>- Philips : scientific advisory board (2011)</li> <li>- Radiometer : scientific advisory board (2011)</li> <li>- Abbott : biomarker studies (2011)</li> </ul>
Lopez-Sendon Jose	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : Apixaban: Investigator, Committee member, Consultancy (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : Bisoprolol: Honoraria (2010-2011)</li> <li>- Boehringer-Ingelheim : Dabigatan: Committee member, Consultancy (2010-2011)</li> <li>- Sanofi Aventis : Dronedarone: Investigator, Committee member (2010)</li> <li>- GlaxoSmithKline : Investigator, Committee member (2010-2011)</li> <li>- Servier : Ivabradine: Investigator, Committee member, Consultancy, Honoraria (2010)</li> <li>- Servier : Ivabradine: Investigator, Honoraria (2011)</li> <li>- Daiichi Sankyo : Prasugrel: Investigator, Committee member, Consultancy, Honoraria (2010-2011)</li> <li>- Astra Zeneca : Ticagrelor, Rosuvastatin: Investigator, Committee member, Consultancy (2010-2011)</li> </ul>
Luepker Russell V	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- CVRx : Malignant hypertension (2010)</li> <li>- CVRx : Neurostimulator (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- National Institutes of Health, NHLBI : Medical Research (2010)</li> </ul>
Menasche Philippe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Member of the CEC for TAVI trials (2010-2011)</li> <li>- Boston Scientific : Member of the CEC for the PLATINUM Trial (2011)</li> <li>- Regado Biosciences : Member, Medical Advisory Board (2011)</li> <li>- Regado Biosciences : Member, Medical Advosiry Board (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Menasche Philippe	- Baxter : Member, Steering Committee, Auto-CD34+ Trial (2011)
Mendis Shanthi	None
Morrow David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Anti-ischemic medications (2011)</li> <li>- Menarini : Anti-ischemic medications (2010)</li> <li>- Gilead : Anti-ischemic medications (2010-2011)</li> <li>- Astra Zeneca : Antithrombotic medications (2010)</li> <li>- Boehringer-Ingelheim : Antithrombotic medications (2010)</li> <li>- Johnson &amp; Johnson : Antithrombotic medications (2011)</li> <li>- Genentech : Antithrombotic medications (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : Antithrombotic medications (2010-2011)</li> <li>- Siemens Healthcare : Diagnostic biomarkers (2010)</li> <li>- Instrumentation Laboratory : Diagnostic biomarkers (2010-2011)</li> <li>- Beckman Coulter : Diagnostic biomarkers (2010)</li> <li>- OrthoClinical Diagnostics : Diagnostic biomarkers (2010)</li> <li>- Roche Pharma : Diagnostic biomarkers (2010)</li> <li>- Critical Diagnostics : Diagnostic biomarkers (2011)</li> <li>- Roche Diagnostics : Diagnostic biomarkers (2011)</li> <li>- Novartis : Pharmaceutical remodeling (2010)</li> <li>- Icaria : Pharmaceutical remodeling (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotic medications (2010)</li> <li>- Daiichi Sankyo : Antithrombotic medications (2010)</li> <li>- Eli Lilly : Antithrombotic medications (2010)</li> <li>- Sanofi Aventis : Antithrombotic medications (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Morrow David	<ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic medications (2010)</li> <li>- Merck Sharp &amp; Dohme : Antithrombotic medications (2010)</li> <li>- Beckman Coulter : Diagnostic biomarkers (2010)</li> <li>- Siemens Healthcare : Diagnostics biomarkers (2010)</li> <li>- Singulex : Diagnostics biomarkers (2010)</li> <li>- Roche Pharma : Diagnostics biomarkers (2010)</li> <li>- GlaxoSmithKline : Lipid lowering medications (2010)</li> <li>- Novartis : Pharmaceutical remodeling (2010)</li> <li>- Astra Zeneca : Antithrombotic medications (2011)</li> <li>- Daiichi Sankyo : Antithrombotic medications (2011)</li> <li>- Eli Lilly : Antithrombotic medications (2011)</li> <li>- Sanofi Aventis : Antithrombotic medications (2011)</li> <li>- Bayer Healthcare : Antithrombotic medications (2011)</li> <li>- Merck Sharp &amp; Dohme : Antithrombotic medications (2011)</li> <li>- Athera : Diagnostic biomarkers (2011)</li> <li>- Beckman Coulter : Diagnostic biomarkers (2011)</li> <li>- Abbott Laboratories : Diagnostic biomarkers (2011)</li> <li>- BG medicine : Diagnostic biomarkers (2011)</li> <li>- Siemens Healthcare : Diagnostics biomarkers (2011)</li> <li>- Singulex : Diagnostics biomarkers (2011)</li> <li>- Roche Pharma : Diagnostics biomarkers (2011)</li> <li>- GlaxoSmithKline : Lipid lowering medications (2011)</li> <li>- Novartis : Pharmaceutical remodeling (2011)</li> <li>- Amgen Inc : Pharmaceuticals (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Newby Kristin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Shionogi : nitroglycerin spray (2010)</li> <li>- Novartis : novel antibiotic in development (2011)</li> <li>- Daiichi Sankyo/Eli Lilly : prasugrel (2011)</li> <li>- Johnson &amp; Johnson : rivaroxaban (2011)</li> <li>- Astra Zeneca : ticagrelor (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen Inc : cancer chemotherapeutic (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- National Institutes of Health, NHLBI : cardiovascular, molecular biology grant (2010)</li> <li>- Bristol Myers Squibb : cardiovascular--CEC APPRAISE II (2010)</li> <li>- Astra Zeneca : cardiovascular--CEC PLATO (2010)</li> <li>- Regado Biosciences : cardiovascular--CEC RADAR (2010)</li> <li>- Eli Lilly : cardiovascular--CEC TRILOGY (2010)</li> <li>- GlaxoSmithKline : cardiovascular--PI, SOLSTICE (2010)</li> <li>- Johnson &amp; Johnson : cardiovascular--ROCKET AF biomarkers substudy (2010)</li> <li>- Amylin : diabetes, cardiovascular-- EXCEL trial biomarkers substudy (2010)</li> <li>- David H. Murdock Foundation : genomics; gift to Duke University (2010)</li> <li>- Amgen Inc : cancer chemotherapeutics (2011)</li> <li>- Amylin : exanatide (2011)</li> <li>- GlaxoSmithKline : losmapimod (2011)</li> <li>- Daiichi Sankyo : olmesartan (2011)</li> <li>- Regado Biosciences : PCI; novel anticoagulant (2011)</li> <li>- Eli Lilly : prasugrel (2011)</li> <li>- GlaxoSmithKline : rosiglitazone (2011)</li> <li>- DiaDexus : Lp-PLA2 assays (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Nieminen Markku	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Orion : Heart failure (2010)</li> <li>- DCRI : Heart Failure (2011)</li> <li>- Orionpharma : Heart Failure (2011)</li> <li>- TIMI group : Trombosis (2011)</li> </ul>
Ohman E Magnus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Liposcience : Diagnostic tests (2010-2011)</li> <li>- WebMD : Online health information provider (2010-2011)</li> <li>- Astra Zeneca : Pharmaceuticals (2010-2011)</li> <li>- Boehringer-Ingelheim : Pharmaceuticals (2010-2011)</li> <li>- Sanofi Aventis : Pharmaceuticals (2010-2011)</li> <li>- Gilead : Pharmaceuticals (2010-2011)</li> <li>- Medicines Company : Pharmaceuticals (2010-2011)</li> <li>- Bristol Myers Squibb : Pharmaceuticals (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : Pharmaceuticals (2010-2011)</li> <li>- Pozen : Pharmaceuticals (2010-2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Pharmaceuticals (2010)</li> <li>- Eli Lilly : Pharmaceuticals (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Maquet : Medical technology/products (2010)</li> <li>- Daiichi Sankyo : Pharmaceuticals (2010)</li> <li>- Eli Lilly : Pharmaceuticals (2010)</li> <li>- Maquet : Medical technology/products (2011)</li> <li>- Daiichi Sankyo : Pharmaceuticals (2011)</li> <li>- Eli Lilly : Pharmaceuticals (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Parkhomenko Alexander	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Servier : ivabradin, trimetazidin (2011)            - Servier : Ivabradine (2010)            - Bayer : xarelto (2011)</p> <p>D - Research funding (departmental or institutional).            - Boehringer-Ingelheim : dabigatran (2010)</p> <p>E - Research funding (personal).            - BHFZ : corvitin (soluble ukrainian quercetin) (2010)            - BHFZ : corvitin (2011)</p>
Pinto Fausto Jose	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Boehringer-Ingelheim : Dabigatran (2010-2011)            - Servier : Ivabradine (2010)            - Servier : Ivabradine, Perindopril (2011)            - Astra Zeneca : Ticagrelor (2011)            - GE Healthcare : Ultrasound equipment (2010-2011)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Servier : Ivabradine (2010)            - Medtronic : CRT (2011)            - Servier : Ivabradine (2011)</p> <p>D - Research funding (departmental or institutional).            - Servier : Ivabradine (2010)            - GE Healthcare : Ultrasound equipment (2010)            - Medtronic : CRT (2011)            - Servier : Ivabradine (2011)            - GE Healthcare : Ultrasound equipment (2011)</p>
Ravkilde Jan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Astra Zeneca : ADP-receptor blocker (2010-2011)</p>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Ravkilde Jan	- Eli Lilly : ADP-receptor blocker (2010-2011)
Robertson Rose Marie	None
Rosamond Wayne	None
Simoons Maarten L	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : anti angina (2010) - Astra Zeneca : anti thrombotic (2010) - Boehringer-Ingelheim : anticoagulant (2010-2011)
Smith Sidney	None
Steg Philippe Gabriel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : antianginal agents (2010) - Bayer : anticoagulants (2010) - Astellas : Anticoagulants (2010) - Eisai : antiplatelet agent (2010) - Astra Zeneca : antiplatelet agents (2010) - Daiichi Sankyo : antiplatelet agents (2010) - Boehringer-Ingelheim : antithrombotics (2010) - Sanofi Aventis : antithrombotics (2010) - GlaxoSmithKline : antithrombotics (2010) - Medicines Company : antithrombotics (2010) - Bristol Myers Squibb : antithrombotics (2010) - Merck Sharp & Dohme : Antithrombotics (2010) - Pfizer : heart failure (2010) - Amgen : Lipid lowering treatment (2010) - Medtronic : stents (2010)  D - Research funding (departmental or institutional). - Servier : Registry on coronary artery disease (2010)

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Aspirin, Rivaroxaban (2010)</li> <li>- Bayer : Aspirin, Rivaroxaban (2010)</li> <li>- Amgen : Darbopietin (2010)</li> <li>- Servier : Ivabradine, Phase II investigational products (2010)</li> <li>- TIMI group : Rivaroxaban (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2010)</li> <li>- TIMI group : Rivaroxaban (2010)</li> </ul>
Thygesen Kristian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Endpoint Committee (2010-2011)</li> <li>- Servier : Endpoint Committee (2010-2011)</li> <li>- St Jude Medical : Endpoint Committee (2010-2011)</li> <li>- Roche Pharma : Endpoint Committee (2010-2011)</li> <li>- Danish Heart Foundation : Endpoint Committee (2010-2011)</li> <li>- Roche Diagnostics : Speaker fee (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Roche Pharma : Research (2010)</li> <li>- Danish Heart Foundation : Research (2010)</li> <li>- Tryg Fonden : Research (2010)</li> <li>- Danish Heart Foundation : Research (2011)</li> <li>- Tryg Fonden : Research (2011)</li> <li>- Roche Diagnostics : Research (2011)</li> </ul>
Underwood Stephen Richard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- General Electric : Imaging (2011)</li> <li>- Covidien : Radiopharmaceuticals (2011)</li> <li>- Rapidscan Inc : regadenoson (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Underwood Stephen Richard	- Rapidscan Pharma Solutions Inc : regadenoson (2011)
Uretsky Barry	None
Vasilieva Elena	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GlaxoSmithKline : Antithrombotic therapy (2010) - Astra Zeneca : Speaker fees (2011) - GlaxoSmithKline : Speaker fees (2011)
Wallentin Lars	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : Atrial fibrillation (2010-2011) - Boehringer-Ingelheim : Atrial fibrillation (2010-2011) - Pfizer : Atrial fibrillation (2011) - Roche Diagnostics : Biomarkers (2011) - GlaxoSmithKline : Coronary artery disease (2011) - GlaxoSmithKline : Coronary Artery Disease (2010) - Astra Zeneca : Myocardial infarction (2010-2011) - Actelion : Myocardial infarction (2010) - GE Healthcare : Myocardial infarction (2010) - Evolva : Myocardial infarction (2011) - Evolva : Myocardial infarction (2010) - Athera : Myocardial infarction (2010) - Athera : Myocardial infarction (2011) - Roche Pharma : Myocardial infarction (2010) - Regado Biosciences : Myocardial infarction (2010-2011) - Merck Sharp & Dohme : Myocardial infarction (2011) - Merck Sharp & Dohme : Myocardial infarction, Atrial fibrillation (2010)

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Wallentin Lars	<p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Roche Pharma : Myocardial infarction (2010)</li> <li>- Roche Diagnostics : Myocardial infarction (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Atrial fibrillation (2010)</li> <li>- BMS : Atrial fibrillation, Myocardial infarction (2010)</li> <li>- GlaxoSmithKline : Coronary artery disease (2010)</li> <li>- Astra Zeneca : Myocardial infarction (2010)</li> <li>- Merck Sharp &amp; Dohme : Myocardial infarction, Atrial fibrillation (2010)</li> <li>- BMS : Atrial fibrillation (2011)</li> <li>- Boehringer-Ingelheim : Atrial fibrillation (2011)</li> <li>- GlaxoSmithKline : Coronary artery disease (2011)</li> <li>- Astra Zeneca : Myocardial infarction (2011)</li> <li>- Merck Sharp &amp; Dohme : Myocardial infarction (2011)</li> </ul>
Weaver W Douglas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medicines Company : anti paltelet drugs; Trial DSMC (2010)</li> <li>- GlaxoSmithKline : antiinschemia--Trial Steering Committee (2010)</li> <li>- Johnson &amp; Johnson : antiplatelet drugs--Trial DSMC (2010)</li> <li>- Boston Scientific : coronary stents--Trial DSMC (2010)</li> <li>- Symetis SA : DATA and Safety Monitoring Board Clinical Trials (2011)</li> <li>- Medicines Company : DAta and safety Monitoring Board thru DCRI Clinical Trial (2011)</li> <li>- Boston Scientific : Data And Safety Monitoring Board-Clinical Trials (2011)</li> <li>- GlaxoSmithKline : Exec Comm-Clinical Trial (2011)</li> <li>- Symetis SA : valves--Trial DSMC (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulant -DSMC (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Weaver W Douglas	<ul style="list-style-type: none"> <li>- Eli Lilly : anticoagulant--DSMC (2010)</li> <li>- Boehringer-Ingelheim : thrombolysis--Trial DSMC (2010)</li> </ul>
White Harvey	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Regado Biosciences : Antithrombotic (2010-2011)</li> <li>- Merck Sharpe and Dohme : Diabetes (2011)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotic (2010)</li> <li>- Daiichi Sankyo : Antithrombotic (2010)</li> <li>- Eli Lilly : Antithrombotic (2010)</li> <li>- Pfizer : Antithrombotic (2010)</li> <li>- Sanofi Aventis : Antithrombotic (2010)</li> <li>- GlaxoSmithKline : Antithrombotic (2010)</li> <li>- Johnson &amp; Johnson : Antithrombotic (2010)</li> <li>- Schering-Plough : Antithrombotic (2010)</li> <li>- Medicines Company : Antithrombotic (2010)</li> <li>- Bristol Myers Squibb : Antithrombotic (2010)</li> <li>- Roche Pharma : Cholesterol (2010)</li> <li>- Merck Sharp &amp; Dohme : Diabetes (2010)</li> <li>- National Institute for Health Research : Surgery (2010)</li> <li>- Astra Zeneca : Antithrombotic (2011)</li> <li>- Daiichi Sankyo : Antithrombotic (2011)</li> <li>- Eli Lilly : Antithrombotic (2011)</li> <li>- Pfizer : Antithrombotic (2011)</li> <li>- Sanofi Aventis : Antithrombotic (2011)</li> <li>- GlaxoSmithKline : Antithrombotic (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
White Harvey	<ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Antithrombotic (2011)</li> <li>- Schering-Plough : Antithrombotic (2011)</li> <li>- Medicines Company : Antithrombotic (2011)</li> <li>- Bristol Myers Squibb : Antithrombotic (2011)</li> <li>- Roche Pharma : Cholesterol (2011)</li> <li>- Merck Sharp &amp; Dohme : Diabetes (2011)</li> <li>- National Institute for Health Research : Surgery (2011)</li> </ul>
Wijns William	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : device (2010)</li> <li>- Edwards Lifesciences : device (2010)</li> <li>- Terumo Inc : device (2010)</li> <li>- Cordis : device (2010)</li> <li>- Orbus Neich : device (2010)</li> <li>- Astra Zeneca : drug (2010)</li> <li>- Eli Lilly : drug (2010)</li> <li>- GlaxoSmithKline : drug (2010)</li> <li>- Bristol Myers Squibb : drug (2010)</li> <li>- Biosensors : device (2011)</li> <li>- Boston Scientific : device (2011)</li> <li>- Edwards Lifesciences : device (2011)</li> <li>- Terumo Inc : device (2011)</li> <li>- Abbott Vascular : device (2011)</li> <li>- Orbus Nech : device (2011)</li> <li>- Eli Lilly : drug (2011)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Wijns William	<ul style="list-style-type: none"> <li>- GlaxoSmithKline : drug (2011)</li> <li>- Iroko Cardio : pharma (2011)</li> <li>D - Research funding (departmental or institutional).</li> <li>- Cardio3 Biosciences : cell therapy (2010)</li> <li>- Boston Scientific : device (2010)</li> <li>- Medtronic : device (2010)</li> <li>- St Jude Medical : device (2010)</li> <li>- Biotronik : device (2010)</li> <li>- Abbott Laboratories : device (2010)</li> <li>- Therabel : drug (2010)</li> <li>- Ablynx : nano antibodies (2010)</li> <li>- Cardio3 Biosciences : cell therapy (2011)</li> <li>- Boston Scientific : device (2011)</li> <li>- Medtronic : device (2011)</li> <li>- St Jude Medical : device (2011)</li> <li>- Biotronik : device (2011)</li> <li>- Abbott Laboratories : device (2011)</li> <li>- MICELL : device (2011)</li> <li>- Therabel : drug (2011)</li> </ul>
Wood David Allan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Pharma : Rheumatoid arthritis; Alectazar (2010)</li> <li>- Bayer Schering Pharma : 3rd ESC Asia CVD Symposium (2010)</li> <li>- Kowa : Atherosclerosis (2011)</li> <li>- Astra Zeneca : Crestor - Lipid Modification (2010-2011)</li> <li>- Zentiva : Generic Drug Manufacturer (2010)</li> </ul>

## Universal Definition of MI (TF28) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Wood David Allan	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Niacin - Lipid Modification (2010-2011)</li> <li>- Chugai Pharma UK : Rheumatoid arthritis (2010)</li> <li>- Pfizer : Varenicline - Smoking Cessation (2010)</li> <li>D - Research funding (departmental or institutional).</li> <li>- Pfizer : Varenicline - smoking cessation (2010)</li> <li>- Pfizer : Varenicline - smoking cessation (2011)</li> </ul>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

## Universal Definition of MI (TF28) - Document Reviewers

Expert	Type of Relationship with Industry
Almahmeed Wael Abdulrahman	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2011)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2011)</p>
Arnar David O	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Cardiac Electronic Devices (2011) - Astra Zeneca : Cardiovascular Therapeutics (2011) - Boehringer-Ingelheim : Cardiovascular Therapeutics (2011) - Sanofi Aventis : Cardiovascular Therapeutics (2011)</p>
Barili Fabio	None
Bloch Kenneth	None
Bolger Ann	None
Botker Hans Erik	None
Bozkurt Biykem	<p>D - Research funding (departmental or institutional). - NIH (National Institute of Health) : DEVELOPMENT OF A LAB-ON-A-CHIP SYSTEM FOR SALIVA-BASED DIAGNOSTICS (2011)</p>
Bugiardini Raffaele	None
Cannon Christopher Paul	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Product (for CME symposium) (2011) - Pfizer : Product (for scientific symposium) (2011) - Novartis : Product (funds donated to charity) (2011) - Bristol Myers Squibb : Product (funds donated to charity) (2011) - Alnylam : Product (funds donated to charity) (2011)</p> <p>C - Receipt of royalties for intellectual property. - Automedics Medical Systems : Product (2011)</p> <p>D - Research funding (departmental or institutional). - Astra Zeneca : Product (2011)</p>

## Universal Definition of MI (TF28) - Document Reviewers

Expert	Type of Relationship with Industry
Cannon Christopher Paul	<ul style="list-style-type: none"> <li>- GlaxoSmithKline : Product (2011)</li> <li>- Takeda Pharmaceuticals : Product (2011)</li> <li>- Merck Sharp &amp; Dohme : Product (2011)</li> <li>- Accumetrics : Product (2011)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : Product (2011)</li> <li>- Merck Sharp &amp; Dohme : Product (2011)</li> <li>- Essentialis : Product (2011)</li> </ul>
De Lemos James A	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Acute Coronary Syndromes (2011)</li> <li>- Bristol Myers Squibb : Acute Coronary Syndromes (2011)</li> <li>- Astra Zeneca : consulting for acute coronary syndromes (2011)</li> <li>- Daiichi Sankyo : Endpoint committee (2011)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Abbott Laboratories : Biomarkers (2011)</li> <li>- Roche Diagnostics : Biomarkers (2011)</li> </ul>
Eberli Franz Robert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Atorvastatin (2011)</li> <li>- Cordis : CCVI (2011)</li> <li>- Ablynx : CEC ALX 0081 Trial (2011)</li> <li>- AGA medical : CEC PC Trial (2011)</li> <li>- Eli Lilly : Prasugrel (2011)</li> <li>- Astra Zeneca : Ticagrelor (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Coronary and Electrophysiologic Trials (2011)</li> <li>- Biotronik : Educational Grant (2011)</li> <li>- Medtronic : Registries (2011)</li> </ul>

## Universal Definition of MI (TF28) - Document Reviewers

Expert	Type of Relationship with Industry
Eberli Franz Robert	<ul style="list-style-type: none"> <li>- Terumo Inc : Stent Trial (2011)</li> <li>- Abbott : Stent Trials (2011)</li> <li>- Biosensors : Stent Trials (2011)</li> </ul>
Escobar Edgardo	None
Hlatky Mark	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medicines Company : bivalirudin (2011)</li> <li>- Gilead : ranolazine (2011)</li> </ul>
James Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : coagulation inhibition (2011)</li> <li>- Astra Zeneca : Platelet inhibition (2011)</li> <li>- Eli Lilly : platelet inhibition (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : platelet inhibition (2011)</li> <li>- Eli Lilly : platelet inhibition (2011)</li> <li>- Medtronic : thrombus asp catheter (2011)</li> <li>- Terumo Inc : thrombus asp catheter (2011)</li> <li>- Vascular solutions : thrombus asp catheter (2011)</li> </ul>
Kern Karl	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Zoll Medical : Defib, CPR and Temperature Management devices (2011)</li> </ul>
Moliterno David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Symetis SA : Artificial Valve (2011)</li> <li>- Boston Scientific : Stent (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antithrombotic Drugs (2011)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Wiley Blackwell : Textbook (2011)</li> </ul>
Morais Joao	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : antiplatelets (2011)</li> </ul>

## Universal Definition of MI (TF28) - Document Reviewers

Expert	Type of Relationship with Industry
Morais Joao	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulants (2011)</li> <li>- Pfizer : anticoagulants (2011)</li> <li>- Lilly : antiplatelets (2011)</li> <li>- Merck Sharp &amp; Dohme : antiplatelets, lipid lowering (2011)</li> <li>- JaBA Recordati : hypertension (2011)</li> <li>- Servier : ischemic heart disease (2011)</li> </ul>
Mueller Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Acute Heart FAILURE (2011)</li> <li>- BRAHMS GmbH : Diagnostics (2011)</li> <li>- Alere : Diagnostics (2011)</li> <li>- Roche Diagnostics : Diagnostics (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medicines Company : Acute Heart FAILURE (2011)</li> <li>- BRAHMS GmbH : Diagnostics (2011)</li> <li>- Swiss Heart Foundation : Diagnostics (2011)</li> <li>- Beckman Coulter : Diagnostics (2011)</li> <li>- Nanosphere : Diagnostics (2011)</li> <li>- Abbott Laboratories : Diagnostics (2011)</li> <li>- Roche Diagnostics : Diagnostics (2011)</li> </ul>
Neskovic Aleksandar N	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Speaker fees (2011)</li> <li>- Actavis : Speaker fees (2011)</li> <li>- PharmaSwiss : speaker fees (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Ministry of Science and Technology of the Republic of Serbia : Acute Myocardial Infarction unrestricted research grant 2011-2015 (2011)</li> </ul>

## Universal Definition of MI (TF28) - Document Reviewers

Expert	Type of Relationship with Industry
Neskovic Aleksandar N	E - Research funding (personal). - Ministry of Science and Technology of the Republic of Serbia : Acute Myocardial Infarction unrestricted research grant 2011-2015 (2011)
Pieske Burkert Mathias	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2011) - Menarini : Coronary artery disease (2011) - Novartis : Heart Failure (2011)  D - Research funding (departmental or institutional). - Medtronic : Device therapy (2011) - Bayer Healthcare : Heart Failure (2011)
Schulman Steven	None
Storey Robert Frederick	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medscape : Antiplatelet therapy (2011) - Eisai : Atopaxar (2011) - The Medicines Company : Cangrelor (2011) - Novartis : Elinogrel (2011) - Daiichi Sankyo : Prasugrel (2011) - Eli Lilly : Prasugrel (2011) - Astra Zeneca : Ticagrelor (2011) - Iroko Cardio : Tirofiban (2011) - Accumetrics : VerifyNow device (2011) - Merck Sharp & Dohme : Vorapaxar (2011)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Eli Lilly : Prasugrel (2011) - Astra Zeneca : Ticagrelor (2011) - Accumetrics : VerifyNow device (2011)

## Universal Definition of MI (TF28) - Document Reviewers

Expert	Type of Relationship with Industry
Storey Robert Frederick	D - Research funding (departmental or institutional). - Eli Lilly : Prasugrel (2011) - Astra Zeneca : Ticagrelor (2011) - Accumetrics : VerifyNow (2011) - Merck Sharp & Dohme : Vorapaxar (2011)
Taubert Kathryn	None
Tavares Aguiar Carlos Manuel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Aliskiren, Amlodipine/Valsartan (2011) - Bial Portela : Amlodipine/Valsartan (2011) - Servier : Ivabradine (2011) - Daiichi Sankyo : Olmesartan, Prasugrel (2011) - JaBA Recordati : Pitavastatin (2011) - Lilly : Prasugrel (2011) - Astra Zeneca : Rosuvastatin (2011) - Bayer : Rvaroxaban (2011)
Vranckx Pascal	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Coronary artery devices (2011)
Wagner Daniel R	D - Research funding (departmental or institutional). - Abbott : Stents (2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2010-2011)</li> <li>- AGA : Devices for catheter treatment of congenital heart defects (2010)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : transcatheter valve implantation (2010)</li> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2011)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2011)</li> </ul>
Bax Jeroen	<ul style="list-style-type: none"> <li>- Heart.org : Education (2010)</li> <li>- Astra Zeneca : Farma (2010)</li> <li>- Servier : Farma (2010)</li> <li>- Philips : Imaging (2010)</li> <li>- GE Healthcare : Imaging (2010)</li> <li>- Lantheus Inc : Imaging (2010)</li> <li>- Boston Scientific : Pacing (2010)</li> <li>- Medtronic : Pacing (2010)</li> <li>- St Jude Medical : Pacing (2010)</li> <li>- Biotronik : Pacing (2010)</li> <li>- Impulse Dynamics : Pacing (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2010)</li> <li>- Edwards Lifesciences : Heart Valves (2010)</li> <li>- GE Healthcare : Imaging (2010)</li> <li>- Lantheus Inc : Imaging (2010)</li> <li>- Boston Scientific : Pacing (2010)</li> <li>- Medtronic : Pacing (2010)</li> <li>- St Jude Medical : Pacing (2010)</li> <li>- Biotronik : Pacing (2010)</li> <li>- Servier : Farma (2011)</li> <li>- Edwards Lifesciences : Heart Valves (2011)</li> <li>- GE Healthcare : Imaging (2011)</li> <li>- Lantheus Inc : Imaging (2011)</li> <li>- Boston Scientific : Pacing (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Medtronic : Pacing (2011)</li> <li>- St Jude Medical : Pacing (2011)</li> <li>- Biotronik : Pacing (2011)</li> </ul>
Cecconi Claudio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Pharmaceutical (2010-2011)</li> </ul>
Deaton M Christi	<ul style="list-style-type: none"> <li>- St Jude Medical : Cath lab - speaker X 1 (2010)</li> <li>- Daiichi Sankyo : consultant for patient adherence 2009-10 (2010)</li> <li>- Eli Lilly : consultant for patient adherence 2009-10 (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : medicines for diabetes (2010)</li> <li>- Novo-Nordisk : patients with heart failure and diabetes (2011)</li> </ul>
Fagard Robert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Honorarium for manuscript (2011)</li> <li>- Servier : Honorarium for manuscript in Medicographia (2010)</li> </ul>
Funck-Brentano Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis CH : Adjudication Committee on an immunosuppressant (2011)</li> <li>- Lundbeck : Cardiac safety of an antidepressant (2011)</li> <li>- Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2010-2011)</li> <li>- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2010-2011)</li> <li>- Johnson &amp; Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials.</li> <li>- MMV (CH) : Cardiac Safety of an antimalarial drug (2010-2011)</li> <li>- Santhera (CH) : Cardiac Safety of an antimalarial drug (2010-2011)</li> <li>- Sigma Tau : Cardiac Safety of an antimalarial drug (2010-2011)</li> <li>- TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2010-2011)</li> <li>- CEPHALON : DSMB in an oncology phase IIb trial (2010-2011)</li> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2010-2011)</li> <li>- Intracellular Therapies USA : Psychotropic drug development (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel (2010)</li> </ul>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Enoxaparin (2010)</li> <li>- Boehringer-Ingelheim : Pradaxa (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Bayer : Rivaroxiban (2011)</li> <li>- Astra Zeneca : Ticagrelor (2011)</li> <li>- Eli Lilly : Effient (2011)</li> </ul>
Hoes Arno	<ul style="list-style-type: none"> <li>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips</li> <li>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from</li> <li>D - Research funding (departmental or institutional).</li> <li>- Bayer Healthcare : unrestricted grant for diagnostic kits in suspected cardiovascular disease (2010)</li> <li>- Abbott Laboratories : unrestricted grant for diagnostic kits in suspected cardiovascular disease (2010)</li> <li>- Roche Pharma : unrestricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome (2010)</li> <li>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2011)</li> </ul>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : cardiovascular (2011)</li> <li>- Boehringer-Ingelheim : cardiovascular (2011)</li> <li>- Daiichi Sankyo : cardiovascular (2011)</li> <li>- Medtronic : cardiovascular (2011)</li> <li>- St Jude Medical : cardiovascular (2011)</li> <li>- Sanofi Aventis : cardiovascular (2011)</li> <li>- Meda pharma : cardiovascular (2011)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2011)</li> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2011)</li> <li>- Sanofi Aventis : cardiovascular (2011)</li> <li>- Meda pharma : cardiovascular (2011)</li> </ul>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lantheus Inc : Imaging tracers (2010)</li> <li>- Lantheus Inc : Perfusion imaging tracer development (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : Development of imaging agents (2010)</li> <li>- Novartis : Development of imaging agents (2010)</li> <li>- GE Healthcare : Development of imaging agents (2010)</li> <li>- Lantheus Inc : Development of imaging agents (2010)</li> <li>- Roche Pharma : Drugs for brain diseases (2010)</li> <li>- Astra Zeneca : Neurology (2011)</li> <li>- GE Healthcare : Neurology and molecular imaging (2011)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antiarrhythmic agents (2010)</li> <li>- Merck Sharp &amp; Dohme : Antiarrhythmic agents (2011)</li> <li>- Astra Zeneca : Antiplatelet agents (2010-2011)</li> <li>- Bristol Myers Squibb : Antiplatelet agents (2010)</li> <li>- Regado Biosciences : Antithrombotic agents (2010-2011)</li> <li>- Abbott : coronary stents (2010)</li> <li>- Abbott Vascular : Coronary stents (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2010)</li> <li>- Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Cardiac valves (2010)</li> <li>- Medtronic : Cardiac valves (2010)</li> <li>- St Jude Medical : Cardiac valves (2010)</li> <li>- Siemens Healthcare : Imaging (2010)</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices (2010)</li> <li>- Edwards Lifesciences : Cardiac valves (2011)</li> <li>- Medtronic : Cardiac valves (2011)</li> <li>- St Jude Medical : Cardiac valves (2011)</li> <li>- Boston Scientific : Coronary stents (2011)</li> <li>- Siemens Healthcare : Medical imaging (2011)</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
McDonagh Theresa	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Vifor International : Ferrinject (2010-2011)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabridine (2010) - Servier : Ivabridine (2011)</p> <p>D - Research funding (departmental or institutional). - Biotronik : CRT (2010)</p>
Popescu Bogdan Alexandru	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging (2010-2011)</p>
Reiner Zeljko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulants (2011) - Bayer Healthcare : anticoagulants (2010) - Abbott : antilipemics (2010) - Astra Zeneca : antilipemics (2010-2011) - Pfizer : antilipemics (2010-2011) - Sanofi Aventis : antilipemics (2011) - Abbott Laboratories : antilipemics (2011) - Merck Sharp &amp; Dohme : antilipemics (2010) - Merck Sharp &amp; Dohme : antilipemics (2011)</p>
Sechtem Udo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2010-2011) - Daiichi Sankyo : Antiplatelet therapy (2010) - Novartis : Drugs (2010-2011) - Pfizer : Drugs (2011) - Siemens Healthcare : Imaging (2010) - General Electric : Imaging (2010)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Imaging devices (2010) - Johnson &amp; Johnson : Stents (2010) - Novartis : Drugs (2011) - Johnson &amp; Johnson : Stents (2011)</p>
Sirnes Per Anton	

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : clinical studies atrial fibrillation investigator fee (ROCKET) (2010)</li> <li>- Merck Sharp &amp; Dohme : investgator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2010)</li> <li>- GlaxoSmithKline : investigator fee, clinical study , SCAD (2010)</li> <li>- Sanofi Aventis : investigator fee, clinical study (PALLAS) (2010)</li> <li>- Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2010)</li> <li>- Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2010)</li> <li>- Boehringer-Ingelheim : investigator fee, clinicla study, AF (RELY. RELYABLE) (2010)</li> <li>- Merck Sharp &amp; Dohme : investgator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2011)</li> <li>- GlaxoSmithKline : investigator fee, clinical study , SCAD (2011)</li> <li>- Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2011)</li> <li>- Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2011)</li> </ul>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Aspirin, Rivaroxaban (2011)</li> <li>- Amgen : Darbopietin (2011)</li> <li>- Servier : Ivabradine, Phase II investigational products (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2011)</li> <li>- TIMI group : Rivaroxaban (2011)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation (2010)</li> <li>- Sanofi Aventis : anticoagulation (2010)</li> <li>- Pfizer : anticoagulation, pulmonary hypertension (2010)</li> <li>- United Therapeutics : Pulmonary arterial hypertension (2011)</li> <li>- GSK : pulmonary arterial hypertension - ambrisentan (2011)</li> <li>- Actelion : pulmonary arterial hypertension - macisentan, selexipag (2011)</li> <li>- Lilly : pulmonary arterial hypertension - tadalafil (2011)</li> <li>- AOP : Pulmonary arterial hypertension - treprostinil (2011)</li> <li>- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat (2011)</li> <li>- Actelion : pulmonary hypertension (2010)</li> <li>- Lilly : pulmonary hypertension (2010)</li> <li>- Bayer Healthcare : pulmonary hypertension, anticoagulation (2010)</li> <li>- Bristol Myers Squibb : thromboembolic disease - Apixaban (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2011)</li> <li>- Sanofi Aventis : Thromboembolic disease (2011)</li> </ul>
Vahanian Alec	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : valve disease (2011)</li> <li>- Valtech : valve disease (2011)</li> <li>- Medtronic Foundation : valve disease (2011)</li> <li>- saint Jude medical : valve disease (2011)</li> <li>- Edwards Life sciences : valve disease (2011)</li> <li>- Abbott : Valve prostheses (2010)</li> <li>- Boehringer-Ingelheim : Valve prostheses (2010)</li> <li>- Edwards Lifesciences : Valve prostheses (2010)</li> <li>- Medtronic : Valve prostheses (2010)</li> <li>- Valtech : Valve prostheses (2010)</li> <li>- Siemens Healthcare : Valve prostheses (2010)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drug (2010-2011)</li> <li>- Eli Lilly : Antiplatelet drug (2010-2011)</li> <li>- Abbott : Stent (2010-2011)</li> <li>- Biosensors : Stent (2010-2011)</li> <li>- Boston Scientific : Stent (2010-2011)</li> <li>- Medtronic : Stent (2010-2011)</li> <li>- Biotronik : Stent (2010-2011)</li> <li>- Cordis : Stent (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Stent (2010)</li> <li>- Biosensors : Stent (2010)</li> <li>- Medtronic : Stent (2010)</li> <li>- Cordis : Stent (2010)</li> <li>- St Jude Medical : OCT (2011)</li> <li>- Abbott : Stent (2011)</li> <li>- Biosensors : Stent (2011)</li> <li>- Medtronic : Stent (2011)</li> <li>- Biotronik : Stent (2011)</li> </ul>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	- Cordis : Stent (2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.